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Abstract 
Annotation and Function of Switch-like Genes in Health and Disease 
Adam M. Ertel 
Aydin Tozeren, Ph.D. 
 
 
 
 
Gene expression microarrays provide transcript-level measurements across entire 
genomes and are traditionally used for differential expression analysis between health 
and disease or classification of disease subtypes. The abundance of gene expression 
microarray data currently available to the scientific community makes it possible to 
assess gene transcript levels among diverse tissue types for an entire genome. Gene 
expression is controlled over a wide range at the transcript level through complex 
interplay between DNA and regulatory proteins, resulting in gene expression profiles that 
can be represented as normal, graded, and bimodal (switch-like) distributions.  It is our 
assertion that these distributions of gene expression, notably the bimodal distribution, 
result from biologically relevant regulation events.  We have performed genome-scale 
identification and annotation of genes with bimodal, switch-like expression at the 
transcript level in human and mouse, using large microarray datasets for healthy tissue, in 
order to study the cellular pathways and regulatory mechanisms involving this class of 
genes.  Our method implemented a likelihood ratio test to identify bimodal genes by 
comparing the best-fit two-component normal mixture, estimated using the expectation 
maximization algorithm, against a single-component normal distribution for each gene. 
This procedure identified roughly 15% of genes in human and mouse as bimodal, with a 
substantial overlap between human genes and their orthologous mouse counterparts. A 
survey of biological pathways revealed that the set of bimodal genes plays a role in cell 
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communication and signaling with the external environment. Our analysis of regulatory 
sequence regions for bimodal genes revealed characteristics including enrichment of 
TATA boxes and an increased number of alternative transcription start sites.  In addition 
to regulatory sequence analysis, we explored aspects of epigenetic regulation for their 
activity among the set of bimodal genes. We performed meta-analysis of gene expression 
microarray, DNA methylation, and histone methylation datasets representing human stem 
cells and liver tissue to reveal that the mode of expression within switch-like genes is 
primarily associated with histone methylation status. These results provide insight to 
normal patterns of histone methylation in healthy, differentiated tissue types. Aberrant 
methylation is a known marker in the progression of cancer, so these switch-like genes 
may also provide a valuable reference in disease diagnosis and prognosis. The method 
presented for bimodal gene identification also allows for an alternate approach to 
differential gene expression analysis between tissues and disease subtypes.  
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Chapter 1: Background 
1.1 Motivation 
With the advent of high-throughput assays for gene expression, it is possible to identify 
alterations in biological pathways as a result of disease by surveying the expression of 
genes that participate in those pathways [1-3].  While changes expression on an 
individual gene bases lack consistency among sample populations, changes at the 
pathway level are more consistent and provide insight towards identifying the underlying 
mechanisms of the disease process [2, 3].  However, concerted changes among several 
genes in a common pathway can result directly from a disruption of healthy cell function 
or they may be an indirect consequence as the cell processes shift their throughput to 
compensate for perturbations arising from the disease process [4, 5].  In order to further 
understand direct versus indirect changes in gene expression, we aim to identify the range 
of expression for genes as they are regulated in both their active state as well their 
inactive state. 
 
1.2 Gene expression 
Gene expression at the mRNA transcript-level is controlled by regulatory molecules and 
molecular complexes that work in different combinations to produce multiple cellular 
phenotypes.  These diverse combinations of expression levels result in patterns that can 
be used to identify characteristics of the broader biological pathways in which they 
participate [3, 6].  Early gene expression assays, such as the electrophoresis gel-based 
northern blot, provided single-gene measurements that could be compared across several 
conditions.  Advancements in chemistry and miniaturized fabrication technology resulted 
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in the ability to manufacture gene expression microarrays, consisting of thousands of 
oligonucleotide probes cable of surveying multiple transcripts simultaneously [7, 8].   
 
 
Figure 1: Two-color microarray experiment workflow 
 
Microarray systems can be separated into two distinct types – those using either single-
channel or two-channel nucleotide detection.  Two-channel microarrays, illustrated in 
Figure 1 (adapted from National Institutes of Health), are used to hybridize two 
biological samples, each labeled with a different wavelength fluorescent dye.  The 
difference in intensity between the fluorescent dyes hybridized to each probe provides a 
measurement of differential transcript expression.  This approach is useful for 
highlighting the relative differences between two biological samples, but is not as reliable 
for detecting absolute levels of expression [9].   
No differential expression
Expressed
Repressed
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Figure 2: Single-channel Affymetrix GeneChip microarray 
 
Single-channel microarrays employ a single fluorescent dye and the intensity of each 
probe provides an absolute expression measure.  Single-channel arrays may also be used 
for differential analysis between two samples, but require twice as many microarrays.  
Custom made and commercially available platforms are used for both single- and two-
channel microarray experiments.  Affymetrix is a manufacturer of widely used 
oligonucleotide expression arrays, the Affymetrix GeneChip, illustrated in Figure 2 
(adapted from [10]).  The Affymetrix GeneChip design uses a combination of short 
nucleotide sequences (25 bases long) that are organized into probesets targeting specific 
features along the length of a transcript.  A probe set for a single transcript typically 
contains 20 unique perfect-match probes intended to measure biological signal, and 
mismatch probes that are identical to the perfect match probes with the exception of one 
base, to correct for non-specific background signals.  These high-density arrays contain 
probes capable of measuring hundreds of thousands of sequence features. 
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1.3 Microarray Analysis 
Gene expression microarrays allow expression levels to be measured simultaneously for 
thousands of gene transcripts, resulting in complex molecular profiles.  Gene expression 
studies face the challenge that prior knowledge is often incomplete and the number of 
measured genes far exceeds the number of samples, resulting in an underdetermined 
system.  Microarray analysis techniques must address the multiple-testing problem 
resulting from the large number of simultaneous measurements performed on a gene 
expression microarray.  Analysis techniques also need to account for a high level of 
variation inherent to biological data.  A good microarray study design will include 
biological replicates to capture variation between individual organism technical as well as 
technical replicates to account for variation introduced by the measurement system.  
However, the high cost of performing a microarray experiment often limits the number of 
samples to less than the ideal.  Sample preprocessing and normalization prior to analysis 
helps to reduce, but not eliminate, problems arising from bias in the variation (Microarray 
normalization is discussed in further detail in Chapter 2).  Approaches to microarray data 
analysis, such as those aimed at differential analysis between health and disease or 
classification of disease subtypes, must account for the effects of variance over a large 
number of expression measurements.  Successful approaches to genome-scale gene 
expression microarray data often rely on statistical methods such as machine learning in 
order to organize genes and samples by similar patterns of expression or to identify 
discriminative gene vectors within a small number of conditions. 
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1.3.1 Differential Analysis 
Differential analysis of gene expression microarray data is used to identify the underlying 
differences between two biological conditions.  The simplest approach to differential 
analysis is expression fold change between the samples for two conditions.  This 
approach does not have a statistical basis, and therefore does not capture variation in the 
data or provide a false discovery rate estimate [11, 12].  Statistical methods such as 
Student’s t-test, analysis of variance (ANOVA), the Wilcoxon rank sum test, and 
Significance Analysis of Microarrays (SAM) provide more robust measures of expression 
differences.  SAM is currently the most commonly used algorithm for differential 
expression analysis [13].  SAM is a t-test-based method developed specifically for 
microarrays that provides statistical robustness and a false discovery rate estimated 
directly from the data by permuting sample membership between the differential 
conditions [14].  This method allows a user to adjust the number of significant genes 
selected for output based on the desired false discovery rate.  The set of genes, or 
features, identified by differential analysis can then be used as a set of biomarkers or 
interpreted for biological insight. 
 
1.3.2 Clustering Analysis 
Cluster analysis was introduced as a visualization and discovery tool for gene expression 
analysis [15].  Patterns of expression across several biological samples allow similarly 
expressed genes to be grouped into biologically related groups, under the paradigm that 
genes participating in a common function are activated simultaneously.  Additionally, 
biological samples can be grouped together based on similar molecular profiles (Figure 
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3).  Hierarchical clustering and K-means clustering are algorithms commonly used to 
group samples and genes together based on their similar expression profiles.  Hierarchical 
clustering requires the selection of a distance threshold to separate patterns into clusters, 
while in K-means clustering the number of clusters K is a user-selected parameter [16].  
The distance metric used to measure similarity between gene expression patterns is also 
selectable, with Euclidean distance and Pearson correlation among the most common 
metrics.  Clustering by genes has been a successful approach, taking advantage of linear 
relationships between genes under common regulatory control.  This has helped identify 
genes of previously unknown function by grouping them with genes of well-described 
function [17].  These groups of functionally related genes have also been used to define 
subsets of the genome that contain statistically overrepresented sequence motifs that 
represent putative transcription factor binding sites [18].  With an increasing number of 
biological samples, it is evident that many genes are co-regulated in only a subset of 
conditions, as these genes may participate in several biological processes, and are 
influenced by a combination of regulatory signals [19].  A limitation of basic clustering 
techniques is that genes are assigned to a unique cluster while several clusters might 
actually share a common biological control within a subset of conditions.  Approaches 
such as Bayesian decomposition attempt to unify groups of genes based on these 
common controls and allows genes to belong to multiple groups with associated weights 
for each [20].  These existing approaches have been successful in reducing the high-
dimensionality of microarray data and organizing genes into groups with coherent 
biological function.  While these relationships provide a great deal of insight, they are 
suited for generalization and may not capture intricacies of biological variation.  Further 
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descriptions of gene expression are required to understand how different patterns of 
expression accomplish necessary biological functions across diverse conditions and tissue 
types.  
 
 
Figure 3: Hierarchical clustering performed on both genes and samples. 
 
1.3.3 Gene Expression Distributions 
The availability of publically accessible gene expression microarray data has grown 
exponentially over the past decade [21].  The large amount of microarray data currently 
available to the scientific community makes it possible to compare genome-wide 
transcript levels for hundreds of tissue types and disease states.  This large amount of data 
provides a context for representing the distribution of transcript expression levels in 
healthy organisms,  where they may either be tightly regulated within a narrow range, or 
fluctuate widely as a function of environmental cues or tissue specialization.  
Ubiquitously expressed “housekeeping” genes have been identified as those highly 
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expressed with little variation across conditions [22-24].  Experimental techniques have 
demonstrated that changes in gene expression levels can occur continuously or in a 
binary switch-like manner in response to extracellular changes [25, 26].  While breadth of 
expression and housekeeping behavior have been established using genome-scale 
measurements, these descriptions of graded and binary genes have been produced using 
primarily single-gene studies.   Consistent with findings obtained in single-gene studies, 
gene expression distributions across microarray samples appear as normal, graded, and 
bimodal (switch-like), as shown in Figure 4. 
 
1.3.4 Tissue Specific Expression 
Towards a description of contextual gene expression, efforts to explain biological 
functions associated with single genes or sets of related genes often focus on variations of 
gene expression across diverse tissue types.  Tissue-specific regulation accounts for a 
majority of the differences in gene expression across biological samples.  Identification 
of genes as tissue-selective and tissue-specific is useful for highlighting their biological 
function, as well as providing reference/context for disease states.  Identification of 
tissue-specific and tissue-selective genes is commonly based on present/absent calls, 
requiring a global threshold [27-29].  Tissue-specific behavior has also been identified 
using statistical tests to compare sample distributions between tissue types [23, 30, 31].  
Other approaches have used a numeric value representing the degree of tissue specificity 
within one tissue or tissue subset versus all others [32, 33].  These studies are typically 
performed on a small number of samples within each tissue type, and effectively describe 
genes with large variation between distinct tissues.   
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Figure 5: Hierarchical organization of GO term “integral to membrane” 
 
1.4 Functional Annotation 
Gene expression microarrays provide a tool for the investigation of complex diseases, in 
which the underlying disease process results from a disruption of healthy regulatory 
signals.  While several events are required for a biological pathway to function properly, 
it can take only one change in these events to disrupt the functionality.  In diseases such 
as cancer, where disruptions in cell signaling are prevalent, several studies have focused 
on the identification of disease markers in the form of single-gene or protein signatures.  
These studies, however, have encountered large variability in gene and protein levels 
within disease subtypes.  In the context of functionally related groups, however, 
expression increases and decreases surveyed across groups of functionally related genes 
prove to be more consistent.  Biological annotation tools, such as Gene Ontology (GO) 
[34] or Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways [35], allow 
changes in individual genes to be mapped onto biological functions where their 
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significance can be evaluated using functional enrichment analysis [1].  GO provides a 
controlled vocabulary describing a gene and gene product in any of three contexts: 
biological process, cellular component, and molecular function.  Within each of these 
three contexts, terms are organized within a hierarchy following the rules of an acyclic 
graph.  The GO hierarchy is structured into several levels of detail, allowing genes and 
gene products to be described at a very broad level of detail down to a level representing 
direct interaction, as depicted in Figure 5.  The annotations contained in GO are limited 
to those describing the biology of healthy organisms.  In contrast, pathways annotated in 
the KEGG database represent molecular interactions in healthy biology as well as disease 
states.  KEGG pathways provide a graphical representation of biological pathways and 
cellular localization, where nodes are used to represent objects such as gene products and 
edges between nodes represent biological relationships such as activation and inhibition, 
as shown for the gap junction pathway in Figure 6.  In addition to knowledge-based gene 
annotation, biologically related sets of genes have been determined experimentally and 
are curated within the Molecular Signatures Database (MSigDB).  MSigDB provides 
gene sets organized by disease types and response to chemical perturbation and is 
integrated into the Gene Set Enrichment Analysis (GSEA) pipeline [36].  GSEA 
identifies the significance of a priori gene sets within microarray data using a weighted 
Kolmogorov-Smirnov test.  These techniques are sensitive to differential expression as 
well as small concerted changes in levels of gene expression.  Microarray data is most 
informative when it can be placed in the context of existing knowledge, whether that 
consists of functional biological annotation or expression signatures for well-understood 
biological conditions [37].  As pathway-level organization of genes offers better 
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consistency among biological samples and also provides a tool to interpret the biology, 
information describing how pathways are utilized in different ways among different 
tissue types is lacking.  While it is clear that prior biological knowledge is incomplete, it 
is also apparent that the available microarray data is far from saturated.  An abundance of 
information is required to evaluate gene expression in context, in order to determine 
whether changes in gene and pathway activity is a cause, effect, or compensation for the 
disease process. 
 
 
Figure 6: KEGG diagram illustrating nodes and edges for the gap junction pathway
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Chapter 2: Microarray normalization and reproducibility 
 
2.1 Summary 
This chapter discusses the considerations and approaches used for combining datasets 
obtained from different experimental labs and different microarray platforms.  Variation 
in biological source material and normalization schemes that attempt to correct for 
sources of variation are presented.  The workflow used for combining the datasets used in 
Chapters 4 and 5 is discussed here in detail. 
 
2.2 Introduction 
Analysis of gene expression microarrays requires the separation of molecular profiles that 
appear as a result of a controlled condition or treatment those that appear as a result of 
noise or external factors.  On the most basic level, the normalization required for 
differential analysis of microarray data produced on the same platform under the same 
experimental procedures conducted will control the average intensity level and variance 
of the data.  As more comprehensive biological studies require an abundance of data, it is 
often desirable to recycle data obtained on older platforms or to combine data from 
several sources.  Many platforms, both commercial and custom-made, are used in 
experimental labs and comparing the results obtained from different platforms and 
procedures is a considerable challenge.  Reproducibility has been studied extensively 
across datasets from multiple platforms, and normalization schemes have been devised to 
minimize systemic variability between datasets.  Nevertheless, a large number of 
limitations remain and several considerations must be addressed when comparing or 
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combining microarray datasets.  There are different considerations for reproducibility 
between experiments designed around two-channel platforms versus those designed 
around single-channel platforms.  Two-channel platforms are best suited for relative 
differential expression analysis between two conditions.  While absolute expression 
estimates can be obtained from two-channel microarrays by applying additional 
calibration steps, the single-channel platforms are specifically designed to provide 
absolute expression measures.  For the remainder of the text, only single-channel 
microarrays are considered, with attention to Affymetrix oligonucleotide arrays.   
 
2.3 Reproducibility across Experiments and Platforms 
Several studies have been performed to evaluate the consistency of microarray data 
obtained on different platforms or in different laboratories, but results have been mixed.  
Many early studies into the reproducibility of microarray data demonstrated poor 
consistency across different platforms [38, 39].  Later studies addressed discrepancies 
resulting from experiments being performed in different laboratories and found a good 
level of reproducibility between platforms [40, 41].  Discrepancies identified in older 
studies can also be attributed to platform-specific measures of absolute expression.  
Absolute expression measures are offset by platform-dependent probe effects that can be 
corrected for by considering relative expression measures [40, 41].  Among the platforms 
compared across several laboratories, Affymetrix microarray platforms have been shown 
to achieve better accuracy than other array types [40, 41].  Additionally, newer 
Affymetrix microarray platforms have improved accuracy and precision of expression 
measurements [41].  Gene expression quality improvements have also been realized 
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through probe set annotation updates [42, 43].  While reproducibility is an issue across 
platforms and experimental laboratories, so is the accuracy of absolute expression 
measures.  The ability of a microarray to detect transcript levels depends on the probe 
design, manufacturing precision, and chemistry.  Different platforms therefore have 
different accuracy and reliability.  The lower limit for transcript abundance measurable 
by oligonucleotide microarrays is estimated between 1 and 10 copies per cell [44].  It is 
estimated that microarrays provide an accurate measurement for 70-90% of genes, 
provided they are above the detection threshold [44].  With this detection accuracy, there 
still remains an issue of reproducibility across platforms, where absolute expression 
measures may be represented with a different scale or offset.  Even over generations of 
microarrays that use common probesets, some reproducibility is lost.  Although 
correlation approaching 99% has been demonstrated between older Affymetrix 
HGU133A and newer HGU133plus2 arrays, slight differences in absolute expression 
measure have been identified for nearly half of the probesets common between these two 
arrays [45].    
 
2.4 Normalization 
Normalization is a necessary step for removing bias and reducing the effects of 
undesirable variation in microarray data analysis.  There are several aspects of transcript-
level measurements that require robust preprocessing and normalization techniques.  
Preprocessing addresses the probe intensity measures include a degree of background 
signal that should be removed in order to more accurately represent the absolute level of 
expression.  Each probe sequence contributing to a probe-set intensity measurement may 
16 
 
exhibit a unique affinity, referred to as probe effect.  Normalization brings the total 
transcript level represented on each microarray within an experiment to the same overall 
levels. 
 
2.4.1 MAS5 algorithm 
The Affymetrix microarray pipeline includes data management and analysis software.  
With the Microarray Suite 5 (MAS5) software, Affymetrix introduced the now widely 
used MAS5 statistical algorithm.  Affymetrix microarray probesets are designed with 
perfect match (PM) and mismatch (MM) probes, which are used in combination to 
estimate and remove signal attributed to non-specific binding.  Predecessors of the MAS5 
algorithm simply subtracted the MM value from the PM value, which sometimes resulted 
in negative transcript level estimates.  MAS5 corrected this problem by truncating 
negative values.  Additionally, MAS5 provided a statistical basis for determining 
present/absent/marginal transcript calls from each probe set based on a one-sided signed 
rank test [46].  While these estimates are statistically sound, studies have shown that 
these present/absent/marginal calls do not always provide a reliable filter for gene 
expression levels [47-49].  Many criticisms faced by the PM-MM scheme have been 
addressed by the Robust Multichip Average (RMA) preprocessing approach [50-52].  
The successor to Affymetrix MAS5 software, Affymetrix® Expression Console™ 
Software, includes both MAS5 and RMA algorithms. 
 
17 
 
2.4.2 Robust Multichip Average Expression Measure 
An alternate approach to background correction independent of probe MM values was 
introduced by the RMA algorithm.  Rather than rely on differences between PM and MM 
probes, RMA performs background correction based on a parametric model [51].  This 
approach was shown to provide more stable measurements when compared against PM-
MM correction [50, 52].  RMA achieves additional stability by performing batch 
normalization over all arrays in a dataset.  The RMA algorithm consists of three steps: 
background correction, quantile normalization, and summarization.  Background 
correction is applied to each microarray on an individual basis.  The background signal is 
modeled as an Epanechnikov distribution and subtracted from the distribution of PM 
signals.  Probe quantiles on each array are then replaced with the average quantiles 
computed across all arrays.  The final step is summarization, where median polish is 
performed within each probe set across all arrays to remove the effect of outliers.  RMA 
is widely used and has been shown to perform as well as or better than alternative 
methods [53]. 
 
2.4.3 Robust Multichip Average for Large Datasets 
Implementations of the RMA algorithm typically have a downside limiting the number of 
microarrays that can be processed based on the amount of computer memory available.  
Additionally, adding new samples to microarray dataset requires that all the samples are 
renormalized together.  Both these issues arise from RMA computing average quantiles 
and row effects across all arrays in an analysis.  Workarounds exist for both these issues, 
and the implementation of these workarounds is described herein.   
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Raw microarray data includes hundreds of thousands of probe intensities per array.  
Normalization techniques that compute averages over all arrays in a dataset must handle 
several gigabytes of data for larger datasets.  When computer memory is not sufficient to 
hold this amount of data, hard disk swap space can be used.  A subset of n from the total 
number of microarrays N is loaded into memory and quantiles are computed as a 
cumulative average.  The rank of each probe is then stored within tiles of data across the 
whole dataset, in swap files containing m probesets and n arrays.  Once the average 
quantiles are computed across all arrays, they are mapped onto each array using the rank 
value.  The RMA algorithm performs the summarization step separately for each 
individual probe set.  Therefore, not all probesets need to be retained in memory at one 
time.  The tiled data for m out of a total M probe sets is loaded into memory and used to 
perform median polish and compute summary values for the final data table.  An 
overview of the RMA workflow is presented in Figure 7. The quantile values and the row 
effect values produced during the median polish are also retained.   If this procedure is 
performed on a sufficiently large set of microarrays, the quantile and row effect values 
can be applied to additional arrays without renormalizing the entire dataset.   
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Figure 7: Overview of the refRMA workflow 
 
The application of RMA quantiles and row effects to additional samples was 
demonstrated as a practical approach when a sufficiently large dataset was used to 
compute these values [54, 55].  The utility of this approach, referred to as the refRMA 
workflow, relies on a training dataset of biologically diverse samples [55].  Biologically 
diverse samples are required to represent the full scale of variation.  By establishing 
quantiles and row effects on a training set of 200 microarrays, additional samples 
processed using the refRMA workflow show over 99% correlation when compared to 
RMA values computed from only those additional samples [55].   This approach provides 
flexibility for handling increasing large datasets while retaining the robustness of the 
original RMA algorithm. 
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Chapter 3: Pathway-specific differences in gene expression 
 
3.1 Summary 
This chapter presents an analysis of biological pathway-specific differences in gene 
expression between normal tissue, tumor tissue, and cultured cell-lines.  This material has 
been adapted from work performed with colleague Arun Verghese and published in BMC 
Molecular Cancer [56].  Cell lines are used in experimental investigation of cancer but 
their capacity to represent tumor cells has yet to be quantified. The aim of the study was 
to identify significant alterations in pathway usage in cell lines in comparison with 
normal and tumor tissue.  This study utilized a pathway-specific enrichment analysis of 
publicly accessible microarray data and quantified the gene expression differences 
between cell lines, tumor, and normal tissue cells for breast, CNS, colon, ovary, prostate, 
and renal tissue.  Significant gene lists were identified using Significance Analysis of 
Microarrays (SAM) and tested for enrichment along KEGG pathways for all pair-wise 
comparisons between cell lines, tumor, and normal tissue.  Cellular pathways that were 
significantly upregulated in cell lines compared to tumor cells and normal cells of the 
same tissue type included ATP synthesis, cell communication, cell cycle, oxidative 
phosphorylation, purine, pyrimidine and pyruvate metabolism, and proteasome. Results 
on metabolic pathways suggested an increase in the velocity nucleotide metabolism and 
RNA production. Pathways that were downregulated in cell lines compared to tumor and 
normal tissue included cell communication, cell adhesion molecules (CAMs), and ECM-
receptor interaction.  Only a fraction of the significantly altered genes in tumor to normal 
comparison had similar expressions in cancer cell lines and tumor cells. Significantly 
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altered genes in tumors compared to normal tissue were largely tissue specific.  Among 
these genes downregulation was a major trend. In contrast, cell lines contained large sets 
of significantly upregulated genes that were common to multiple tissue types.  The three-
way pathways comparison presented in this study brings light into the differences in the 
use of cellular pathways by tumor cells and the cancer cell lines used to model 
tumorigenesis in vitro. 
 
3.2 Background 
Cell lines derived from tumors and tissues comprise the most frequently used living 
systems in research on cell biology. Limitations on the abundance of tissue samples 
necessitate the use of animal models and cell lines in the studies of tumor-related 
phenomena. Cancer cell lines have been extensively used in screening studies involving 
drug sensitivity and effectiveness of anti cancer drugs [57]. Other studies using cultured 
cells aimed at the determination of the phenotypic properties of cancer cells such as 
proliferation rates, migration capacity and ability to induce angiogenesis [58]. In other 
studies, human cultured cells were used to create tumors in the mice models [59]. 
 
Whether measurements on cell lines provide information about the metastatic behavior of 
cancer cells in vivo is currently under investigation. Unsupervised classification of gene 
expression profiles of cancer tissue and cancer cell lines result in separate clustering of 
cancer cell lines from tissue cells for both solid tumors and blood cancers [60]. Sets of 
genes responsible for differences between solid tumors and cell lines in their response to 
anti cancer drugs have been identified in the Serial Analysis of Gene Expression (SAGE) 
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Database [61]. Most optimal cell lines to represent given tumor tissue types were 
determined with the use of a quantitative tissue similarity index [62]. Results were 
striking: only 34 of the 60 cell lines used in the analysis were most similar to the tumor 
types from which they were derived. The study provided valuable information about 
selection of most appropriate cell lines in pharmaceutical screening programs and other 
cancer research. In a more recent work Sandberg et al. [63] identified those gene function 
groups for which cell lines differed most significantly from tumors based on meta-
analysis using Gene Ontology (GO) [34]. Genes involved in cell-cycle progression, 
protein processing and protein turnover as well as genes involved in metabolic pathways 
were found to be upregulated (an increase in expression reflected by mRNA transcript 
levels) in cell lines, whereas genes for cell adhesion molecules and membrane signaling 
proteins in cell lines were downregulated (a decrease in expression reflected by mRNA 
transcript levels) in comparison with tumors [63]. To build on this approach, functional 
enrichment analysis based on Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathways [64, 65] can be used to illustrate causal relationships between genes (gene 
products). While GO is organized into hierarchical annotations in the context of normal 
cellular function, the KEGG database organizes the genes (gene products) into pathway 
reaction maps and functional complexes, including some disease-specific pathways. 
 
The present study focuses on pathway specific differences in gene expression patterns 
between cancer cell lines and tumors as well as cancer cell lines and normal tissue and 
tumors and normal tissue. Extension of microarray data analysis to three-way comparison 
allows for the identification of gene expression patterns unique to cell lines. Such patterns 
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might have arisen due to factors related to the cell culture environment. We used publicly 
accessible microarray data available for normal and cancer tissues and associated NCI60 
cell lines in a pathway-specific quantitative analysis of gene expression profiles. A 
dominant theme that emerged from our analysis was that pathway-specific gene 
expression differences between cancer cell lines and cancer tissue were similar both in 
magnitude and direction to corresponding differences between cell lines and normal 
tissue cells. Cell cycle associated differences between normal and tumor tissue were 
amplified in cell lines. Results on metabolic pathways suggested an increase in the 
velocity of RNA and DNA production and increased flow of metabolites in the oxidative 
phosphorylation pathway.  On the other hand, a small fraction of significantly altered 
genes in tumor-to-normal comparison had similar expressions in cancer cell lines and 
tumor cells. These genes were tissue-specific and were positioned sparsely along multiple 
pathways. 
 
3.3 Materials and methods 
3.3.1 Microarray datasets 
Microarray datasets used in this study consisted of the publicly accessible gene 
expression profile dataset for NCI60 cell lines [66] and similar data for a panel of tumors 
and normal tissue samples [67].  This dataset contains measurements obtained using the 
Affymetrix Hu6800 arrays (Table 1). The tissue types considered in this study (breast, 
CNS, colon, prostate, ovary, and renal tissue) were restricted to those where the 
microarray results were available for normal and tumor tissue as well as corresponding 
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cell lines. MDA-MB-435 and MDN cell line samples were excluded from these datasets 
because their tissue of origin, previously thought to be breast, is now suspect [62]. 
 
3.3.2 Quality of probe set annotations 
Quality of the Hu6800 GeneChip annotation was assessed because this platform is 
several versions away from current human microarrays. While the Hu6800 design is old 
and probe designs have since been greatly improved, the quality of probe annotation is 
maintained through regular updates by Affymetrix. The annotations used in this study are 
based on a July 12th 2006 update of Affymetrix annotations according to the March 2006 
(NCBI Build 36.1) version of the human genome. A comparison was done between gene 
annotations for the Hu6800 GeneChip obtained from Webgestalt (web-based gene set 
analysis toolkit) [68] and from the Affymetrix website on August 7th, 2006. Out of the 
7129 probesets on the chip, 6058 had the same annotations from both Webgestalt and 
Affymetrix. Of the remaining 1071 probesets, 692 were not annotated, 288 were 
annotated in the Affymetrix list but not in Webgestalt, 28 were annotated in Webgestalt 
but not Affymetrix, and 63 (~1%) probesets had conflicting annotations in Webgestalt 
and Affymetrix. Only 42 (~0.70% of all genes) genes belonging to any known KEGG 
pathway had discrepancies between Webgestalt and Affymetrix. While there were very 
few probes with discrepant annotations in any given pathway, this list of 42 probes was 
enriched for Antigen processing and presentation, Natural killer cell mediated 
cytotoxicity, Cell adhesion molecules (CAMs), Type I diabetes mellitus, and SNARE 
interactions in vesicular transport pathways. A review of this probe list revealed that 
discrepancies were merely due to updates and minor revisions to the official gene symbol 
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that may reflect increased understanding of these genes functions. Genes associated with 
KEGG pathways represent a subset of well-studied and sequenced genes. Overall, the 
probe sets of genes belonging to KEGG pathways have well established and reliable 
annotations on the Hu6800 GeneChip. Annotations retrieved from Webgestalt were used 
for the remainder of the analysis. 
 
3.3.3 Normalization 
Gene expression data was normalized for each tissue type by computing the Robust 
Multichip Average (RMA) [50, 52] directly from the Affymetrix .CEL files for cell line, 
tumor, and normal samples. RMA consists of three steps: a background adjustment, 
quantile normalization and finally summarization. Quantile normalization method utilizes 
data from all arrays in an experiment in order to form the normalization relation [50, 52]  
RMA generated expression measure is on the log base 2 scale. 
 
Normalized data was generated using the Bioconductor (package for R) [69] 
implementation of RMA. R 2.3.1 [70] was first installed on an Intel Xeon machine 
running a Windows Professional Operating System. The Biobase 1.10.1 (dated 20 June 
2006) package which contains the base functions for Bioconductor was installed by 
accessing the getBioC.R script directly from the Bioconductor website [71].  The 
"readaffy" command was used to load all .CEL files for a single tissue type. The RMA 
expression measures for each tissue type were computed using the "rma" function with 
default settings, including the Perfect Match Adjustment Method setting as Perfect Match 
Only so that expression signal calculation was based upon the perfect match values from 
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each probe set as described in [52]. The RMA computed expression values were written 
out to a comma separated text file. 
 
The resulting expression values for each sample were checked against the average 
expression across cell line, tumor, and normal populations by calculating their correlation 
coefficients. Two anomalous samples (one normal tissue sample from colon and one 
tumor sample from prostate) were identified having correlations well outside the 
remaining population (R < 0.9) and removed; RMA for those tissues was recomputed 
excluding the suspect samples. The RMA generated gene expression data for the 
Affymetrix chips was clustered using a hierarchical clustering algorithm with Pearson 
correlation coefficient as the distance metric using average linkage using TIGR MeV 
Version 3.1. For each of the six tissues under consideration, the cell line samples 
clustered together in a single branch distinct from the branches containing tumor and 
normal tissue samples. This result confirmed that all the cell line samples have 
characteristics that are significantly different from the tumor tissue. 
 
3.3.4 Significance analysis for gene expression 
The Significance Analysis of Microarray Data (SAM) implementation [14] in the TIGR 
MeV Version 3.1 software [72] was used to identify those genes that had statistically 
significant differences in expression between tumor samples, cell lines, and normal 
tissue. SAM analysis was performed using all default parameters and adjusting the delta-
value to obtain a maximum number of genes while maintaining a conservative false 
discovery rate of zero. A list of significant genes was identified for cell line-tumor cell 
27 
 
line-normal and normal-tumor combinations for each of the six tissue types. When the set 
of significant genes was deleted from the microarray data, clustering analysis based on 
the remaining genes interspersed microarray datasets for cell lines with corresponding 
datasets for tissue. 
 
3.3.5 Identification of significantly altered pathways 
Two different methods were used for identifying significantly altered pathways. First, 
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways [64, 65] were identified 
as significantly altered by performing a functional enrichment analysis on genes 
identified as significant by SAM analysis. The analysis was carried out using the 
Webgestalt system [68], comparing significant genes obtained by SAM against all genes 
in the Affymetrix HU6800 array, for each comparison under study. A p-value for 
pathway enrichment was obtained using the hypergeometiric test documented in [68].  
Four different p-value cutoffs (0.001, 0.01, 0.05 and 0.1) were used in order to assess the 
dependence of the significant pathway identification on p value. This process was also 
applied to subsets of significant genes, for example, the intersection of significant genes 
from (CL - N) and (T - N). 
 
A second method was applied to KEGG pathway genes in order to detect changes that 
were not apparent on a single-gene basis. For this method, KEGG pathways were deemed 
significantly altered if at least 80% of the genes for that pathway contained on the 
HU6800 array were shifted in the same direction for a given comparison. For each of the 
six tissues, three-way comparisons were performed between averaged cell line, tumor, 
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and normal samples. Similar examples of how significant changes in functional pathways 
are revealed by a population of related genes that are not evident from observations of a 
single gene are found in [3, 73]. 
 
Table 1: Microarray data presented by Staunton et al. and Ramaswamy et al. used 
in the three way comparison of gene expression patterns in cell lines, tumors and 
normal tissue. 
  Cell lines*   Normal tissue** Tumor tissue** Array 
Breast 6 5 10 Affymetrix 
CNS 6 5 20 Affymetrix 
Colon  7 10 9 Affymetrix 
Ovary 6 4 9 Affymetrix 
Prostate 2 7 7 Affymetrix 
Renal 8 11 8 Affymetrix 
Sum 35 42 63   
 
*    Data obtained from Staunton et a l [10]   
** Data obtained from Ramaswamy et al [11]  
 
3.4 Results 
3.4.1 Significant genes 
This article presents a pathway-specific analysis of gene expression profile differences 
between cancer cell lines and normal and tumor tissue. The microarray data used in the 
three-way comparison of gene expression profiles covered breast, CNS, colon, ovary, 
prostate, and renal tissue (Table 1). Gene expression profiles of cancer cell lines derived 
from this data clustered together in a branch exclusive of tumor and normal tissue within 
each tissue type and for all tissue types combined. Lists of significant genes (SAM genes) 
were determined using SAM analysis from the microarray data pairs of cell lines and 
tumors (CL - T), cell lines and normal tissue (CL - N) and tumor and normal tissue (T - 
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N) for each of the six tissue types under consideration. Table 2 provides a summary of 
the numbers of significant genes for the three-way comparison. The table shows that the 
significant genes for (CL - T) and (CL - N) pairs ranged in numbers from low hundreds 
to thousands, depending on the tissue type. Significant genes for (T - N) pairs were lower 
in number than those for (CL - T) and (CL - N) pairs in all six tissues under 
consideration. Downregulation of significant genes was a trend in (T - N) comparisons 
while a majority of SAM genes were upregulated in cell lines compared to tumor and 
normal (CL - T; CL - N). Moreover, an overwhelming majority of the SAM genes in (T - 
N) comparison were not found as significantly altered in (CL - T) comparisons. The gene 
 
Table 2: Number of significant genes identified by SAM in comparisons of cell line-
to-tumor (CL – T), cell line-to-normal (CL – N), and tumor-to-normal (T – N) 
comparisons.  The percentage of upregulated genes is shown in parentheses for cell line-
to-tumor (CL – T), cell line-to-normal (CL – N), and tumor-to-normal (T – N) 
comparisons.  The intersection (CL – T ∩ CL – N) contains genes that were altered in 
cell lines compared to both normal and tumor tissue, representing expression profiles that 
are specific to cell lines.  The set (T – N) - (T – N ∩ CL – T) contains SAM genes in the 
(T – N) comparisons that are not significantly altered in (CL – T) comparisons.  The set 
(T – N ∩ CL – N) - (T – N ∩ CL – N ∩ CL – T) contains genes significantly altered in 
both cell lines and tumors relative to normal tissue (T – N; CL – N) but with no 
significant difference between cell lines and tumor tissue (CL – T); tumor-specific 
expression profiles that may be adequately modeled by cell lines.   
Comparison Breast CNS Colon Ovary Prostate Renal 
Common 
Genes 
CL-T 
 (upregulated %) 
572 
(66%) 
576
(86%) 
503
(62%) 
603
(41%) 
190 
(94%) 
1637 
(44%) 
51 
CL-N 
 (upregulated %) 
269
(61%) 
560
(72%) 
983
(63%) 
225
(62%) 
469 
(72%) 
2047 
(45%) 
29 
T-N 
 (upregulated %) 
243
(10%) 
153
(61%) 
166
(45%) 
94
(14%) 
30 
(0%) 
65 
(0%) 
0 
CL-T ∩ CL-N 132 328 431 145 164 1481 16 
(T-N) - (T-N ∩ CL-T) 236 138 143 83 26 43 0 
(T-N ∩ CL-N)  
- (T-N ∩ CL-N ∩ CL-T) 
31 43 64 26 9 28 0 
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set (T - N) - (T - N ∩ CL - T) listed in Table 2 shows a vast majority of SAM genes in (T 
- N) comparison are not significantly altered in expression in (CL - T) comparison, 
suggesting that cancer cell lines may be good representation models for tumor cells in 
gene expression profile studies. On the other hand, the set (CL - T) contains many more 
genes than the (T - N) comparison, revealing that cancer cell lines have a large number of 
genes that are significantly altered in expression compared to tumor cells. The same trend 
holds true when cell lines are compared with normal tissue cells. These results indicate 
that global gene expression profiles of cultured cancer cell lines contain significantly 
different gene expression patterns compared to the corresponding profiles for normal and 
tumor tissue. 
 
SAM genes common in (CL - T) comparisons for all six tissues were all upregulated.  
Table 3shows the list of 51 significant genes in (CL - T) comparisons that are common to 
the six tissue types under consideration. In this list of 51 genes, the overrepresented 
KEGG pathways with a p-value cutoff of 0.01 are cell cycle, oxidative phosphorylation, 
proteasome, pyrimidine metabolism, and ubiquitin mediated proteolysis. The 18 genes 
shown in italics also appeared among 29 significant genes that were common to all (CL - 
N) comparisons. The 18 genes common to both lists again showed overrepresentation of 
cell cycle and ubiquitin mediated proteolysis pathways under a p-value cutoff of 0.01. 
Moreover these eighteen genes showed the same trend of upregulation in cell line-to-
tumor (CL - T) and cell line-to-normal (CL - N) comparisons. No significant genes 
identified in the (T - N) comparisons were common to all six tissues.  
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Table 3: SAM genes that were upregulated in cell lines compared to tumors in all 
the 6 tissues considered in the study (CL – T).  SAM genes shown in italic also 
belonged to cell lines and normal tissue comparison.  There were no downregulated genes 
common to all tissue types in cell line-tumor (CL – T) comparisons. 
Gene 
Symbol Gene Name Kegg Pathway(s) 
ATP5B ATP synthase, H+ transporting, mitochondrial F1 complex, beta 
polypeptide 
Oxidative phosphorylation, ATP synthesis 
ATP5G3 ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit C3 (subunit 9) 
ATP synthesis, Oxidative phosphorylation 
C1QBP complement component 1, q subcomponent binding protein (Immune Response) 
CBX3 chromobox homolog 3 (HP1 gamma homolog, Drosophila) N/A 
CCNB1 cyclin B1 Cell cycle 
CCT5 chaperonin containing TCP1, subunit 5 (epsilon) N/A 
CDC20 CDC20 cell division cycle 20 homolog (S. cerevisiae) Ubiquitin mediated proteolysis, Cell cycle 
CDKN3 cyclin-dependent kinase inhibitor 3 (CDK2-associated dual 
specificity phosphatase) 
N/A 
CHAF1A chromatin assembly factor 1, subunit A (p150) N/A 
CKAP1 cytoskeleton associated protein 1 N/A 
CKS1B CDC28 protein kinase regulatory subunit 1B N/A 
CKS2 CDC28 protein kinase regulatory subunit 2 N/A 
COX8A cytochrome c oxidase subunit 8A (ubiquitous) Oxidative phosphorylation 
CYC1 cytochrome c-1 Oxidative phosphorylation 
DNMT1 DNA (cytosine-5-)-methyltransferase 1 Methionine metabolism 
DYNLL1 dynein, light chain, LC8-type 1 N/A 
EBNA1BP2 EBNA1 binding protein 2 N/A 
HMGB2 high-mobility group box 2 N/A 
KIAA0101 KIAA0101 N/A 
KIF2C kinesin family member 2C N/A 
LMNB2 lamin B2 Cell communication 
MCM3 MCM3 minichromosome maintenance deficient 3 (S. cerevisiae) Cell cycle 
MCM4 MCM4 minichromosome maintenance deficient 4 (S. cerevisiae) Cell cycle 
MCM7 MCM7 minichromosome maintenance deficient 7 (S. cerevisiae) Cell cycle 
MRPL12 mitochondrial ribosomal protein L12 N/A 
NDUFS8 NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa 
(NADH-coenzyme Q reductase) 
Oxidative phosphorylation 
PAICS phosphoribosylaminoimidazole carboxylase, 
phosphoribosylaminoimidazole succinocarboxamide synthetase 
Purine metabolism 
PCNA proliferating cell nuclear antigen Cell cycle 
POLR2G polymerase (RNA) II (DNA directed) polypeptide G Purine metabolism, RNA polymerase, Pyrimidine 
metabolism 
PRMT1 protein arginine methyltransferase 1 Selenoamino acid metabolism, Nitrobenzene 
degradation, Aminophosphonate metabolism, 
Tryptophan metabolism, Histidine metabolism, 
Androgen and estrogen metabolism, Tyrosine 
metabolism 
PSMA1 proteasome (prosome, macropain) subunit, alpha type, 1 Proteasome 
PSMB2 proteasome (prosome, macropain) subunit, beta type, 2 Proteasome 
PSMB5 proteasome (prosome, macropain) subunit, beta type, 5 Proteasome 
PSMB6 proteasome (prosome, macropain) subunit, beta type, 6 Proteasome 
PSMD14 proteasome (prosome, macropain) 26S subunit, non-ATPase, 14 Proteasome 
RANBP1 RAN binding protein 1 N/A 
SFRS9 splicing factor, arginine/serine-rich 9 N/A 
SNRPA small nuclear ribonucleoprotein polypeptide A N/A 
SNRPB small nuclear ribonucleoprotein polypeptides B and B1 N/A 
SNRPC small nuclear ribonucleoprotein polypeptide C N/A 
SNRPD2 small nuclear ribonucleoprotein D2 polypeptide 16.5kDa N/A 
SNRPD3 small nuclear ribonucleoprotein D3 polypeptide 18kDa N/A 
SNRPE small nuclear ribonucleoprotein polypeptide E N/A 
SNRPF small nuclear ribonucleoprotein polypeptide F N/A 
SNRPG small nuclear ribonucleoprotein polypeptide G N/A 
TCEB1 transcription elongation factor B (SIII), polypeptide 1 (15kDa, 
elongin C) 
Ubiquitin mediated proteolysis 
TUBG1 tubulin, gamma 1 N/A 
TXNRD1 thioredoxin reductase 1 Pyrimidine metabolism 
TYMS thymidylate synthetase Pyrimidine metabolism, One carbon pool by folate 
UBE2C ubiquitin-conjugating enzyme E2C Ubiquitin mediated proteolysis 
UBE2S ubiquitin-conjugating enzyme E2S N/A 
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Figure 8: KEGG pathways identified to be significantly altered in cell lines and 
tumors (CL – T) [  ], cell lines and normal tissue (CL – N) [  ], and tumor and 
normal tissue (T – N) [  ] comparisons.  The term frequency shown in the figure is 
defined as the ratio of tissue types for which a pathway identified as significantly altered 
to the total number of tissue types (6). KEGG pathways were identified as significantly 
altered by using a hypergeometric test with a p-value cutoff. The minimum number of 
SAM genes in each significantly altered pathway has been set to two.  The error bars 
indicate the standard deviation of frequency for different p- value cutoffs (p=0.001, 0.01, 
0.05 and 0.1). 
 
KEGG pathways whose gene expression profiles differed significantly in (CL - T), (CL - 
N), and (T - N) pair comparisons were identified using a hypergeometric test as described 
in the Methods section. Figure 8 shows the most frequently observed KEGG pathways 
with altered gene expression profiles for (CL - T), (CL - N) and (T - N) pairs for breast, 
CNS, colon, ovary, prostate, and renal tissue. Cell cycle and a number of metabolic and 
transcription-related pathways emerged as significantly altered in almost all (CL - T) and 
(CL - N) comparison pairs. Cellular pathways that were significantly altered in cell lines 
compared to tumor cells and normal cells of the same tissue type in at least two tissue 
types included cell cycle, oxidative phosphorylation, purine and pyrimidine metabolism, 
proteasome, ribosome, and RNA polymerase. The most striking difference between cell 
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lines and tumor tissue in Figure 8 is in the oxidative phosphorylation pathway. Oxidative 
phoshorylation is the final stage of cellular metabolism following glycolysis and the citric 
acid cycles. The loss of cancer cell dependence on oxidative metabolism may be an 
important factor in the development of tumors [74]. ECM-receptor interaction, which is 
thought to affect cell migration, appeared with more subtle differences between all 
comparisons (CL - T), (CL - N), and (T - N). This may reflect more tissue-specific 
composition of the migration machinery utilized in tumor cell invasion. 
 
Next we used pathway-specific analysis to identify up- and downregulation patterns in 
three-way comparisons.   
Figure 9 provides module maps showing the direction of regulation of KEGG pathways 
that were identified to be significantly different in at least 2 tissue types in (CL - T) 
comparisons. The pathways presented in Figure 9A were deemed significantly altered if 
the average gene expression between two conditions was altered in the same direction for 
at least 80% of the genes in the pathway. This criterion captured seven of the significant 
pathways from Figure 8 along with 23 additional pathways.   
Figure 9A indicates a high degree of correlation in the direction of Aminoacyl-tRNA 
synthetases, Monoterpenoid biosynthesis, Proteosome, and RNA polymerase pathway 
shifts in cell line – tumor and cell line – normal comparisons. Many more pathways 
appear to be significantly altered in the module map if the criterion for percentage of 
genes altered in the same direction is reduced from 80% to 70% (Figure 9B).  These two 
module maps illustrate how extensive the pathway alterations are in cell lines compared 
to tumor and normal tissue (CL - T; CL - N). 
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The pathway-specific results on cell line-tumor microarray data comparisons presented in 
this study are in agreement with the results recently published by Sandberg et al. [63] on 
the gene expressions patterns associated with gene ontology categories in cell lines and 
tumors. These authors have used the same microarray databases used in our study and 
reached highly similar conclusions on the directions of difference between cell lines and 
tumors along equivalent pathways and gene ontology categories.  Table 4 provides a 
comparison of the KEGG pathways (from Figure 8) against the most related Gene 
Ontology categories from Sandberg et al. [63]. KEGG pathways for complement and 
coagulation cascade and phenylalanine metabolism passed the significance criteria based 
on the (T - N) comparison in our study but we could not located the corresponding GO 
categories in the Sandberg et al. study on cell lines vs. tumor tissue. 
 
 
  
 B
re
as
t
 C
N
S
 C
ol
on
 O
va
ry
 P
ro
st
at
e
 R
en
al
 B
re
as
t
 C
N
S
 C
ol
on
 O
va
ry
 P
ro
st
at
e
 R
en
al
 B
re
as
t
 C
N
S
 C
ol
on
 O
va
ry
 P
ro
st
at
e
 R
en
al
-0.6 -0.8 -0.6 -0.8 0.6 -0.6 0.6 -0.6 -0.6 0.6 0.8 -0.6 -0.6 -0.6 0.6 0.8 -0.6 0.6 Alkaloid biosynthesis I
0.91 0.82 0.86 0.91 0.82 0.91 0.73 0.86 0.82 0.95 0.91 0.91 -0.9 0.68 0.82 0.59 0.59 0.77 Aminoacyl-tRNA synthetases
-0.9 0.57 0.86 -0.7 -0.6 -0.6 -0.7 0.86 0.57 -0.7 -0.7 -0.7 -0.7 -0.6 -0.7 -0.7 -0.6 -0.9 Ascorbate and aldarate metabolism
0.7 0.7 0.83 0.83 0.74 0.83 0.65 0.74 0.87 0.74 0.74 0.83 0.57 0.74 0.61 0.61 -0.5 0.74 Basal transcription factors
0.92 0.62 0.92 0.85 0.54 0.69 0.85 -0.5 0.85 0.92 0.62 0.69 -0.5 -0.6 0.54 0.62 0.77 -0.7 Biosynthesis of steroids
-0.9 -0.8 -0.9 -0.9 -0.9 -0.9 0 -0.9 -0.8 -0.8 -0.9 -0.9 1 -0.9 0.63 0.75 -0.6 -0.8 Blood group glycolipid biosynthesis-lactoseries
-0.8 -0.8 -0.8 -0.8 0 -0.8 0.67 0 -0.7 -0.8 -0.6 -0.8 1 0.67 0.67 -0.6 -0.7 0.58 C21-Steroid hormone metabolism
-0.8 -0.8 -0.9 -0.8 -0.7 -0.7 -0.7 -0.7 -0.8 -0.8 -0.7 -0.7 0.65 0.57 0.55 0.58 0.58 0.61 Cell adhesion molecules (CAMs)
-0.8 -0.7 -0.8 -0.8 -0.7 -0.8 -0.5 -0.5 -0.7 -0.7 -0.7 -0.7 0.69 0.67 0.67 0.64 0.6 0.57 Complement and coagulation cascades
-0.8 -0.7 0 0 -0.7 -0.8 0 -0.8 0 -0.7 -0.7 -0.8 0.67 0 -0.7 0 0.67 -0.7 Ethylbenzene degradation
1 0.8 0.6 1 1 0.8 -0.6 0.6 0.6 1 1 0.8 -1 -0.8 -0.6 0.8 -0.6 -0.8 Glyoxylate and dicarboxylate metabolism
-1 -1 0 -1 1 0 0 1 1 0 1 0 1 1 0 0 0 0 High-mannose type N-glycan biosynthesis
-0.7 -0.7 -0.7 -0.7 -0.9 -0.9 -0.6 -0.6 -0.7 -0.7 -0.9 -0.9 0.86 0.57 -0.6 0.57 -0.6 0.71 Keratan sulfate biosynthesis
-0.8 -0.8 -0.8 -0.8 -0.6 -0.8 0.56 -0.7 -0.9 -0.8 0.56 -0.8 0.94 0.61 0 0.78 0.78 0.83 Linoleic acid metabolism
-0.6 -0.8 -0.9 0 0.55 -0.6 0.73 -0.7 0 -0.5 0 -0.6 0.95 0 0.68 -0.5 -0.6 -0.6 Maturity onset diabetes of the young
-1 -1 -1 -1 0 -1 0 -1 -1 -1 0 -1 1 0 0 0 1 1 Monoterpenoid biosynthesis
-0.8 -0.8 -0.7 -0.8 -0.5 -0.8 0.6 -0.7 -0.7 -0.6 -0.5 -0.8 0.9 0.61 0.62 0.84 0.54 0.57 Neuroactive ligand-receptor interaction
0.8 0.7 0.8 0.8 0.6 0.6 0.6 0.7 0.9 0.8 0.6 0.7 -0.7 0.6 0.7 0.9 0.6 0.6 One carbon pool by folate
1 1 0.96 1 0.96 1 1 1 1 1 1 1 -0.8 0.63 0.93 0.81 0.67 0.78 Proteasome
0.79 0.85 0.77 0.83 0.83 0.79 0.77 0.85 0.81 0.89 0.81 0.83 0.6 0.7 0.81 0.66 0.55 0.66 Pyrimidine metabolism
1 0 0.67 1 0.67 0.83 0.67 0 0.67 1 0.67 0.83 -0.8 -0.7 -0.7 0.83 -0.7 -1 Reductive carboxylate cycle (CO2 fixation)
-1 -1 0 -1 0 -1 -1 0 -1 -1 -1 -1 0 0 -1 0 -1 1 Retinol metabolism
0.97 0.97 0.92 0.95 0.68 0.97 -0.5 0.98 0.92 0.67 0.67 0.97 -0.9 -0.6 0.67 -1 0.55 0.64 Ribosome
0.8 0.9 0.9 0.9 0.9 0.8 0.8 0.9 0.9 0.9 0.8 1 -0.9 0.6 0.8 0 -0.6 0 RNA polymerase
-0.8 -0.7 -0.8 -0.8 -0.7 -0.8 -0.7 0 -1 -0.7 -0.7 -0.8 0.83 -0.7 -0.7 0.83 0.83 0.83 Stilbene, coumarine and lignin biosynthesis
-0.7 -0.8 0 -0.7 0 -0.8 0 -0.8 0.67 0.67 0.67 -0.8 0.83 0 0.83 0 0.83 0 Taurine and hypotaurine metabolism
1 1 1 1 0 0.75 0.75 0 1 1 0 1 -0.8 -0.8 0 -0.8 0.75 0 Terpenoid biosynthesis
-1 0 0 -1 -1 0 -1 0 0 -1 -1 0 0 -1 -1 -1 -1 -1 Tetrachloroethene degradation
-0.8 -0.8 -0.8 -0.7 -0.7 -0.7 -0.6 -0.8 -0.7 -0.7 -0.7 -0.7 0.79 0.6 0.73 0.55 -0.5 0.55 Type I diabetes mellitus
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Figure 9: A module map showing the direction of regulation of cellular pathways 
that were identified as significantly altered in cell lines compared to tumor tissue 
(CL – T) in at least 2 of the 6 tissues considered in this study.  In (A), a pathway is 
deemed significantly altered if at least 80% of the genes in the pathway are shifted in a 
common direction.  In (B), a pathway is deemed significantly altered if at least 70% of 
the genes in the pathway are shifted in a common direction.  The color red indicates an 
upregulated pathway, the color green indicates a downregulated pathway, and the color 
black indicates that the pathway was not significant in that comparison.  
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0.75 1 0.75 0.75 0.75 0.75 -0.6 0.75 0.88 0.88 0.75 0.75 -0.9 -0.9 -0.9 -0.9 -0.6 0 Protein export
0.79 0.85 0.77 0.83 0.83 0.79 0.77 0.85 0.81 0.89 0.81 0.83 0.6 0.7 0.81 0.66 0.55 0.66 Pyrimidine metabolism
1 0 0.67 1 0.67 0.83 0.67 0 0.67 1 0.67 0.83 -0.8 -0.7 -0.7 0.83 -0.7 -1 Reductive carboxylate cycle (CO2 fixation)
-1 -1 0 -1 0 -1 -1 0 -1 -1 -1 -1 0 0 -1 0 -1 1 Retinol metabolism
0.97 0.97 0.92 0.95 0.68 0.97 -0.5 0.98 0.92 0.67 0.67 0.97 -0.9 -0.6 0.67 -1 0.55 0.64 Ribosome
0.8 0.9 0.9 0.9 0.9 0.8 0.8 0.9 0.9 0.9 0.8 1 -0.9 0.6 0.8 0 -0.6 0 RNA polymerase
-0.8 -0.7 -0.8 -0.8 -0.7 -0.8 -0.7 0 -1 -0.7 -0.7 -0.8 0.83 -0.7 -0.7 0.83 0.83 0.83 Stilbene, coumarine and lignin biosynthesis
-0.7 -0.6 -0.7 -0.6 -0.6 -0.6 -0.6 -0.7 -0.9 -0.9 -0.6 -0.6 0.71 -0.7 -0.7 -0.6 -0.7 0.71 Streptomycin biosynthesis
-0.7 -0.8 0 -0.7 0 -0.8 0 -0.8 0.67 0.67 0.67 -0.8 0.83 0 0.83 0 0.83 0 Taurine and hypotaurine metabolism
1 1 1 1 0 0.75 0.75 0 1 1 0 1 -0.8 -0.8 0 -0.8 0.75 0 Terpenoid biosynthesis
-1 0 0 -1 -1 0 -1 0 0 -1 -1 0 0 -1 -1 -1 -1 -1 Tetrachloroethene degradation
-0.8 -0.8 -0.8 -0.7 -0.7 -0.7 -0.6 -0.8 -0.7 -0.7 -0.7 -0.7 0.79 0.6 0.73 0.55 -0.5 0.55 Type I diabetes mellitus
0.62 0.62 0.86 0.76 0.86 0.81 0.52 0.76 0.76 0.9 0.76 0.71 0.52 0.81 0.71 0.76 -0.7 -0.5 Ubiquitin mediated proteolysis
0.56 -0.6 0.78 0.67 0.78 0.56 0.67 0.78 0.78 0.78 0.78 0.56 -0.6 0.56 0.67 0.67 0.67 0.56 Valine, leucine and isoleucine biosynthesis
CL-T CL-N T-N
B) 
36 
 
Table 4: Comparison of results obtained from this study with those based on Gene 
Ontology Processes by Sandberg et al. The symbol [↑] indicates upregulation in cell 
lines with respect to tumors and [↓] indicates downregulation in cell lines with respect to 
tumors (CL – T). 
 
KEGG Pathway Related GO category 
Direction of regulation 
in cell lines with respect 
to tumors 
This study 
Gene 
Ontology 
Study [63] 
ATP synthesis ATP synthesis coupled proton 
transport (GO:0015986) 
↑ ↑ 
Cell cycle Cell cycle (GO:0007049) ↑ ↑ 
One carbon pool by folate Nucleotide biosynthesis 
(GO:0009165) 
↑ ↑ 
Oxidative phosphorylation Oxidative phosphorylation 
(GO:0006119) 
↑ ↑ 
Proteasome Ubiquitin-dependent protein 
catabolism (GO:0006511); 
Modification-dependent protein 
catabolism (GO:0019941) 
↑ ↑ 
Purine metabolism Purine nucleotide metabolism 
(GO:0006163) 
↑ ↑ 
Pyrimidine metabolism Nucleobase, nucleoside, 
nucleotide and nucleic acid 
metabolism (GO:0006139) 
↑ ↑ 
Ribosome Protein biosynthesis 
(GO:0006412) 
↑ ↑ 
RNA polymerase Nucleobase, nucleoside, 
nucleotide and nucleic acid 
metabolism (GO:0006139) 
↑ ↑ 
Cell adhesion molecules 
(CAMs) 
Cell adhesion (GO:0007155) ↓ ↓ 
Cell communication Cell adhesion (GO:0007155) ↓ ↓ 
Complement and coagulation 
cascade 
Complement activation 
(GO:0006956) 
↓ N/A 
ECM-receptor interaction Cell adhesion (GO:0007155) ↓ ↓ 
Focal Adhesion Cell adhesion (GO:0007155) ↓ ↓ 
Phenylalanine metabolism Phenol metabolism 
(GO:0018958) 
↓ N/A 
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3.4.2 Gene expression changes in metabolic pathways 
Metabolic pathways such as oxidative phosphorylation, pyrimidine and purine 
metabolism account for some of the most significant alterations among the three-way 
comparisons. The alterations in the oxidative phosphorylation pathway were discussed 
briefly in the previous section. Purine and pyrimidine metabolic pathways synthesize the 
nucleotides that make RNA and DNA. All of the nitrogens in the purine and pyrimidine 
bases (as well as some of the carbons) are derived from amino acids glutamine, aspartic 
acid, and glycine, whereas the ribose and deoxyribose sugars are derived from glucose. 
Figure 10 shows the KEGG diagram of pyrimidine metabolism with the expression 
values (averaged over six tissues) overlaid for (CL - T) (3a), (CL - N) (3b), and (T - N) 
(3c) comparisons. This KEGG pathway is altered with upregulated expression for a 
majority of genes in cell lines and tumors when compared to normal tissue. The increased 
levels of pyrimidine metabolism gene expression are most pronounced in cell lines (Fig 
3a). A predicted increase in the velocity of RNA and DNA base production in cell lines is 
consistent with trends of increasing rates of cell division observed in cell cultures [75]. 
The observation that nucleotide metabolism accelerates in cancer has been discussed in 
the literature. Development of pyrimidine and purine analogs as potential antineoplastic 
agents evolved from an early presumption that cancer is a disease of uncontrolled growth 
and nucleic acids are involved in growth control [75].
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Figure 10: KEGG pyrimidine metabolism diagram.  Gene expression shifts are projected from comparisons of cell line-to-
tumor (CL – T), cell line-to-normal (CL – N), and tumor-to-normal (T – N) comparisons averaged over all six tissues.  The 
color red indicates upregulated genes, green indicates downregulated genes and grey indicates the genes that are not on the 
microarray.  Uncolored genes are not in the organism-specific pathway for Homo sapiens. A gene is identified as upregulated 
(downregulated) if its gene expression value averaged over 6 tissue types were greater (or lesser) in cell lines compared to tumor or 
normal tissue.  Colored genes with white lettering were also identified with SAM in at least two tissues. 
 
B. (CL – N) C. (T – N) 
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3.4.3 Gene expression pattern changes in cell cycle 
In contrast to the pyrimidine metabolism pathway discussed above, the gene expression 
alterations along the cell cycle pathway appear to be more complex and tissue-specific. 
Figure 11A shows the KEGG diagram of cell division cycle with genes specific to Homo 
sapiens shaded light green. Figure 11B shows the extent of alteration of these genes in the 
three-way comparisons for each tissue type with a graded color map representing 
maximum upregulation in red and maximum downregulation in green. 
 
A) 
 
  
41 
 
B)  
 
Figure 11: KEGG cell cycle diagram.  Genes are shown (a) in a pathway map with 
genes specific to homo-sapiens shaded light green and (b) tabulated with a color map 
showing average gene expression shifts for samples within the six tissues.  Red indicates 
a positive change and green indicates a negative change in average RMA value for the 
respective cell line-tumor (CL – T), cell line-normal (CL – N), and tumor-normal (T – N) 
comparisons, with color scale limits set to -2 and +2. 
  
CL-T CL-N T-N CL-T CL-N T-N CL-T CL-N T-N CL-T CL-N T-N CL-T CL-N T-N CL-T CL-N T-N
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ATM
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GSK3B
HDAC1
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ORC3L
PCNA
PKMYT1
PLK1
PRKDC
RB1
RBL1
RBL2
SFN
SKP1A
SKP2
SMAD2
SMAD3
SMAD4
SMC1L1
TFDP1
TGFB1
TGFB2
TGFB3
TP53
WEE1
YWHAB
YWHAE
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Breast RenalProstateOvaryColonCNS
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Perhaps the most obvious feature of this color map is how subtle the changes in (T - N) 
comparisons are relative to (CL - T) and (CL - N) comparisons in all six tissues under 
consideration. Genes such as CCNA2, CCNB1, CDC20, CDK4, and MDM2 through 
MDM7 are consistently upregulated in cell lines compared to tumors and normal tissue. 
On the other hand, genes such as CCND1, CCND3, CDC16, and CDK2 do not exhibit 
quickly a recognizable pattern. A multitude of gene expression profiles in cell cycle may 
point towards the same disease process. 
 
3.4.4 SAM genes common to cancer cell lines and tumor cells 
It is of interest to cell biologists to identify similarities between cancer cell lines and 
tumors. Towards that goal, one can determine the list of SAM genes belonging to both (T 
- N) and (CL - N) comparisons but do not appear to be significant in (CL - T) 
comparison.  This list is shown in Table 5 for all six tissues under consideration. Table 5 
gives an indication of the size of the SAM gene subsets that are preserved and commonly 
regulated in cell lines and tumors but not in normal tissues. The list of genes in Table 5 
comprises mostly downregulated genes for breast, colon, ovary, prostate, and renal tissue, 
with CNS as the only exception. When these lists were projected onto KEGG pathways, 
the probability of enrichment score could not be used as an indication that the pathways 
are similar because KEGG pathways that include genes from these lists also included 
SAM genes from (CL - T) comparisons. In conclusion, it was not possible to assert 
pathway similarity with statistical confidence using this analysis.  
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Table 5: Genes that were identified by SAM in both (T – N) and (CL – N) comparisons but not in (CL – T) comparisons; (T – 
N ∩ CL – N) - (T – N ∩ CL – N ∩ CL – T). 
 
Breast CNS Colon Ovary Prostate Renal 
UP DOWN UP DOWN UP DOWN DOWN(Cont) UP DOWN UP DOWN UP DOWN 
GALNS APP ACTB ATP5O ARD1A ADH1B PCK1 MCM2 ACTG2   APOD   ADH1B 
GP9 AQP1 CPSF1 COX7A1 ARPC1B BRD2 PLN   AEBP1   CCND2   ALDH4A1 
LCAT ARHGEF6 DDX11 CTNNB1 BCAT1 C7 PPAP2B   C7   CXCL12   ANPEP 
RND2 ATP6V1B2 ECE1 GYPE CCND1 CA2 PPP1R1A   CEBPD   KCNMB1   ASS 
  BRD2 EEF1A1 ITGB7 CPNE1 CALCOCO2 PRKCB1   CNN1   MATN2   ATP6V1B1 
  CTNNB1 EEF1G KIAA0513 CUL7 CASC3 SEPP1   DPYSL2   PTGDS   C7 
  CXCL12 FRAP1 MEF2C ERCC1 CES2 SLC26A3   DUSP1   PTN   CLCNKB 
  DUSP1 GNAI2 MRPS21 GPS1 CHGA SMTN   EGR1   SERPING1   ENG 
  EGR1 GNB1 MYOM2 MDK CLEC3B SPIB   FOS   SPARCL1   EPHX2 
  EGR3 GNB2 PCP4 PDXK CNN1 SRPX   GYPC       FABP1 
  IGFBP4 GPIAP1 PVALB PEX6 CRYAB TACR2   IGFBP5       GATA3 
  JUND GPS1 S100A1 PHLDA2 CTNNB1 TGFBR3   JUNB       GATM 
  KHSRP H3F3B SEPP1 S100A11 CUGBP2 TPM1   LMOD1       GPX3 
  KIT HNRPF SERPINI1 TEAD4 DMD TPM2   LUM       GSTA2 
  KRT15 KHDRBS1     DPYSL2 TSPAN7   MYH11       HMGCS2 
  KRT5 MAZ     FABP4 TUBA3   MYLK       HPD 
  MXI1 NONO     FCGBP ZBTB16   NDN       KCNJ1 
  MYH11 ODC1     FGFR2    NR4A1       MT1G 
  NFIB PCBP2     FHL1    PPAP2B       MT1X 
  NSMAF RAB7     GDI1    SEPP1       PAH 
  PCBP1 RBM10     GPD1L    SERPINF1       PALM 
  SERPINA3 RBM5     HMGCS2    SPARCL1       PCK2 
  SNTB2 RHOB     HSD11B2    TNXB       PRODH2 
  SOX9 SMARCA4     HSPA1A    ZBTB16       PTHR1 
  SPARCL1 SRM     IL11RA    ZFP36       SERPINA5 
  VWF TRIM28     IL6R            TACSTD1 
  ZFP36 TUBB     ITGA7            UGT2B7 
    UFM1     ITPKB            UMOD 
    YBX1     LMOD1              
          LPL              
          MAOA              
          NFIB              
          NR3C2              
             
 
44 
 
3.5 Conclusion 
Our study shows that a large portion of genes implicated in the emergence and 
progression of cancer have similar gene expression values in tumors and cancer cell lines 
indicating the value of cultured cell lines in cancer research. However, the pair-wise 
comparisons of gene expression profiles of CL, T, and N across all tissues illustrate that 
there are pronounced changes in gene expression specific to cell lines (CL - T; CL - N) 
that may not represent a disease process. This study also identified the signaling and 
metabolic pathways in cell lines that have distinctly different gene expression patterns 
than those associated with normal and tumor tissue. Pathway-specific gene expression 
changes in (CL - T) and (CL - N) comparisons were more consistent than (T - N) 
comparisons in the set of six tissues under consideration. Just as the gene expression 
changes in tumor – normal tissue comparison were largely tissue-specific, the 
significantly altered pathways among tumor – normal comparisons were limited to a 
small number of tissues. Functional enrichment analysis allows us to explore significant 
changes in pathways despite having heterogeneous changes in gene expression across 
different tissues. Cellular pathways that were significantly upregulated in cell lines 
compared to tumor cells and normal cells of the same tissue type included ATP synthesis, 
cell cycle, oxidative phosphorylation, purine, pyrimidine and pyruvate metabolism, and 
proteasome. Results on metabolic pathways suggested an increase in the velocity 
nucleotide metabolism and RNA production. 
 
The dominant trend in the gene expression profiles along significantly altered pathways 
in cell lines appeared to be upregulation of genes when compared either to tumor or 
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normal tissue. Exceptions included genes in the cell adhesion molecules, cell 
communication, and ECM-receptor interaction, focal adhesion, and 
complement/coagulation cascade pathways. The apparent downregulation of the 
complement/coagulation cascade in cell lines may be due to the heterogeneous mixture of 
cells in tumor samples including immune cells as well as tissue-specific cells. 
 
The composition of the cell culture medium may be the reason why gene expression 
patterns that differentiate cancer cell lines from tumor tissue are similar to those patterns 
that differentiate between cell lines and normal tissue. Typical cell culture medium is 
replete with metabolites, growth factors, and cytokines, among others, for which cells 
normally must compete in vivo [75]. Multicellular interfaces with which tumor cells 
interact in vivo are not replicated for cells grown in cell culture plates [76-80].  The 
differences in environmental selection pressures may help explain the differential gene 
expression patterns between the tumor tissue and the cell lines. Our finding about the 
upregulation of oxidative phosphorylation in cell lines is supported by previous metabolic 
studies [81, 82]. The documentation of gene expression differences along signaling and 
metabolic pathways is important in compound screening during the drug discovery 
process. Compounds may affect significantly altered pathways between cell lines and 
tumor tissue differently. Recent studies are taking advantage of the technological 
advances in microfluidics and tissue engineering to develop three-dimensional cell 
culture systems that aim simulating in vivo culture conditions. Whether cell lines can be 
made to mimic tumor cell gene expression patterns by altering the culture medium 
conditions is a question yet to be fully explored.  
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Chapter 4: Switch-like genes populate cell communication pathways and are 
enriched for extracellular proteins 
 
4.1 Summary 
This chapter discusses the identification and annotation of bimodal “switch-like” genes in 
the mouse genome and has been adapted from an article published in the BMC genomics 
[83].  Recent studies have placed gene expression in the context of distribution profiles 
including housekeeping, graded, and bimodal (switch-like). Single-gene studies have 
shown bimodal expression results from healthy cell signaling and complex diseases such 
as cancer, however developing a comprehensive list of human bimodal genes has 
remained a major challenge due to inherent noise in human microarray data. This study 
presents a two-component mixture analysis of mouse gene expression data for genes on 
the Affymetrix MG-U74Av2 array for the detection and annotation of switch-like genes. 
Two-component normal mixtures were fit to the data to identify bimodal genes and their 
potential roles in cell signaling and disease progression. Seventeen percent of the genes 
on the MG-U74Av2 array (1519 out of 9091) were identified as bimodal or switch-like. 
KEGG pathways significantly enriched for bimodal genes included ECM-receptor 
interaction, cell communication, and focal adhesion. Similarly, the GO biological process 
"cell adhesion" and cellular component "extracellular matrix" were significantly 
enriched. Switch-like genes were found to be associated with such diseases as congestive 
heart failure, Alzheimer's disease, arteriosclerosis, breast neoplasms, hypertension, 
myocardial infarction, obesity, rheumatoid arthritis, and type I and type II diabetes. In 
diabetes alone, over two hundred bimodal genes were in a different mode of expression 
compared to normal tissue.  This research identified and annotated bimodal or switch-like 
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genes in the mouse genome using a large collection of microarray data. Genes with 
bimodal expression were enriched within the cell membrane and extracellular 
environment. Hundreds of bimodal genes demonstrated alternate modes of expression in 
diabetic muscle, pancreas, liver, heart, and adipose tissue. Bimodal genes comprise a 
candidate set of biomarkers for a large number of disease states because their expressions 
are tightly regulated at the transcription level. 
 
4.2 Background 
Gene expression microarrays have served as a useful tool for assaying large-scale 
similarities and differences among conditions including tissue types [23], stages of 
development [84, 85], and disease states in humans [86, 87] and model organisms [88].  
Initial microarray classification studies such as those presented in [86, 87] were able to 
characterize similarities and differences among samples based on mRNA expression level 
for large gene sets.  More recent studies have made use of biological annotation, such as 
Gene Ontology (GO) [34] or Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathways [89] to project changes in individual genes onto biological functions [56, 63]. 
Existing biological annotation is also a useful supplement to machine learning techniques 
used for determining regulatory connections [20, 90].  These techniques are sensitive to 
differential expression as well as small concerted changes in levels of gene expression, 
yet they may not adequately address changes with respect to the global behavior of gene 
expression – where transcript levels may either be tightly regulated within a narrow 
range, or fluctuate widely as a function of environmental cues or tissue specialization.  
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Efforts to explain biological functions associated with single genes or sets of related 
genes often focus on variations of gene expression across diverse tissue types.  
Identification of genes as tissue-selective and tissue-specific is useful for highlighting 
their biological function, as well as providing reference/context for disease states.  
Identification of tissue-specific and tissue-selective genes is commonly based on 
present/absent calls, requiring a global threshold [27-29].  Tissue-specific behavior has 
also been identified using statistical tests to compare sample distributions between tissue 
types [23, 30, 31].  Other approaches have used a numeric value representing the degree 
of tissue specificity within one tissue or tissue subset versus all others [32, 33].  These 
studies are typically performed on a small number of samples within each tissue type; 
they nevertheless effectively describe genes with large variation between distinct tissues.  
 
Efforts have been made to place gene expression in context of global behavior using 
descriptors such as breadth of gene expression [27]  and distributions characteristics that 
represent ubiquitous, binary, or graded regulation [25, 26, 91-93].  Ubiquitously 
expressed “housekeeping” genes are defined as those highly expressed with little 
variation across conditions, and have been identified in humans using large-scale 
microarray studies [23, 94].  While breadth of expression and housekeeping behavior 
have been established using genome-scale measurements, present descriptions of graded 
and binary genes have typically been produced using single-gene studies [25, 26].  These 
studies have demonstrated that changes in gene expression levels can occur continuously 
or in a binary switch-like manner in response to extracellular changes.  Binary modes of 
gene expression potentially correspond to those proteins with tight regulation at the 
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transcript level.  As such their identification is useful in the exposition of the multiple 
modes of gene expression regulation observed in eukaryotes. 
 
In this study, we expand on the existing literature on gene expression profile distributions 
and determine a comprehensive list of bimodal genes along with their functional 
annotation.  Our preliminary computations based on large collection of human microarray 
data indicated difficulties identifying profiles of bimodal expression due to a great degree 
of subject variability and noise.  For this reason, the present study focuses on murine 
microarray data containing approximately 400 samples, all obtained using the Affymetrix 
MG-U74Av2 platform (Table 6).  This new database allowed us to effectively apply a 
two-component mixture model to hundreds of data points for each gene and identify 
bimodal profiles.  Moreover, bimodal genes with altered modes of expression were 
identified in microarray data for type I and type II diabetes (Table 7) [88, 95-97].  Results 
point to important roles that bimodal (switch-like) genes play within the extracellular 
environment in health and disease.  Bimodal genes, because they are tightly controlled 
around two distinct modes at the transcript level, serve as targets in drug development.  
Moreover, bimodal genes encoding for extracellular proteins may serve as biomarkers in 
targeted proteomic studies. 
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Table 6: Mouse gene expression datasets and tissue types composing our healthy 
dataset. 
 
Healthy Tissue Type Accession No. Source Samples Total 
Adipose 
 
GSE480 GEO 4 6 
GSE2899 GEO 2 
Adrenal GSE1674 GEO 6 6 
Brain GSE3327 GEO 87 89 
GSE480 GEO 2 
Colon GSE2172 GEO 4 5 
E-MEXP-402 Array Express 1 
Epidermal GSE1912 GEO 25 25 
Heart GSE77 GEO 30 38 
GSE4616 GEO 6 
GSE480 GEO 2 
Kidney E-MEXP-495 Array Express 3 3 
Liver E-MEXP-241 Array Express 6 8 
GSE2899 GEO 2 
Lung GSE485 GEO 18 26 
GSE495 GEO 6 
GSE480 GEO 2 
Mammary GSE5831 GEO 9 15 
E-MEXP-892 Array Express 6 
Muscle GSE469 GEO 54 64 
GSE1659 GEO 6 
GSE2899 GEO 2 
GSE480 GEO 2 
Ovary GSE1359 GEO 10 10 
Pancreas GSE769 GEO 3 5 
GSE2899 GEO 2 
Peripheral Blood GSE3039 GEO 12 12 
Small Intestine GSE765 GEO 3 3 
Spleen GSE5306 GEO 12 12 
Stomach E-MEXP-402 Array Express 1 1 
Testis GSE926 GEO 22 49 
GSE640 GEO 17 
GSE1358 GEO 10 
Thymus GSE2585 GEO 8 11 
GSE85 GEO 3 
 All Healthy Tissues 388 
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4.3 Methods 
4.3.1 Data selection 
Murine gene expression datasets (Table 6) were obtained from both the Gene Expression 
Omnibus (GEO,) [21, 98, 99] and ArrayExpress [100, 101] and limited to those providing 
Affymetrix GeneChip MG-U74Av2 data in CEL file format, because datasets are both 
current and abundant for this platform. The resulting dataset contains samples from 
nineteen generalized tissue types. While only one sample was obtained for stomach 
tissue, this does not seem to impact the detection of switch-like or tissue-selective genes 
identified within this tissue. Moreover, stomach tissue clusters with other digestive 
tissues based on the intersection of tissue-selective gene sets, as presented in the results 
section. 
 
4.3.2 Microarray normalization and annotation 
Robust Multichip Average (RMA) [50-52] expression values were computed from these 
CEL files, using RMAExpress software version 0.5 Release [102] with default settings, 
to produce a data table with genes as rows and samples as columns. All CEL files from 
datasets listed in Table 6 were used for normalization, but the data was limited to healthy 
subjects, excluding knockout and disease phenotypes, for subsequent steps in the 
analysis. Annotation for Entrez Gene ID, gene symbol, and KEGG pathway was retrieved 
March 15th, 2007 using Webgestalt (web-based gene set analysis toolkit) [68]. GO 
annotation, as well as missing values for Entrez Gene ID and gene symbol, was 
supplemented from the MG-U74Av2 annotation dated 3/8/2007, obtained directly from 
the Affymetrix website [10] on March 15th, 2007. The data was then imported to Matlab 
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R2006b (The Mathworks Inc., Natick, MA, USA), where all subsequent procedures were 
implemented. 
 
4.3.3 Disease markers, serum proteins, and transcription factor annotation  
Disease gene sets for mouse were obtained from the Rat Genome Database (RGD) 
Disease Portal [103]. Mouse orthologs were obtained for serum protein lists available 
from the Human Proteome Organization (HuPO) Plasma Proteome Project (PPP) [104, 
105]. Entries in the PPP list were converted from International Protein Index (IPI) to 
human Entrez Gene ID using the IPI database for HUMAN, version 3.28, released 20 
Apr 2007 [106, 107]. Mouse orthologs were obtained from this list using Webgestalt. The 
Transfac Professional Database version 11.1 [108, 109] was used to identify genes as 
either transcription factor coding genes or transcription factor targets.  Gene entries, 
including those encoding for transcription factors, were obtained from Transfac Gene and 
limited to those with Entrez Gene IDs represented on the MG-U74Av2 array. 
 
4.3.4 Identification of bimodal genes from estimated parameters for two-component 
mixtures 
Bimodal genes in the murine microarray data (Table 6) were identified using a statistical 
method applied to bimodality in glucose distribution [110, 111]. Briefly, we tested the 
hypothesis H1 that gene expression distribution follows a two-component (bimodal) 
mixture against the hypothesis H0 of a single normal distribution, adjusted for skewness.  
For this purpose, we used the box-cox transformation implemented in Matlab to eliminate 
skewness in RMA-adjusted gene expression histograms for each gene in the microarray 
database [112]. Then we used the expectation maximization (EM) algorithm [113] 
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implemented in Matlab to determine the parameters for the best-fit two-component 
normal mixture for each gene in the database.  The two-component normal mixture is 
used to represent a bimodal distribution, where the parameters µ1 and µ2 are the 
component means, σ1 and σ2 are the component standard deviations and π1 and π2 
represent the proportion of data within each component (note that π2 = 1 - π1).  The 
corresponding parameters for single normal distribution were calculated from the sample 
mean and standard deviation for each gene.  The log likelihood ratio test statistic -2logλ 
was computed for the two-component mixture hypothesis H1 versus the null hypothesis 
H0 of a single component as described in [110, 111].  We estimated the p-values for two-
component mixtures by evaluating the chi-square distribution with six degrees of 
freedom (DF) at the values of -2logλ.  The asymptotic null distribution for the -2logλ 
statistic is typically represented by a chi-square distribution with DF equal to the 
difference in the number of parameters between the null and alternative hypotheses.  
However, regularity conditions for -2logλ do not hold in the case of mixture models, and 
simulation has shown that six DF is a more accurate representation for the asymptotic 
null distribution when testing the alternative hypothesis of two components with unequal 
variance [114].  The choice of six degrees of freedom for testing two components versus 
a single normal provides conservative p-values and was previously used in identifying 
bimodality in blood glucose levels among population subsets [110].  
 
Candidates for bimodal “switch-like” genes were selected as those with p-values no more 
than 0.001, which produced a subset of 2166 out of 9091 unique genes on the MG-
U74Av2 array.  The table in [83] Additional file 1 lists those candidate genes with p < 
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0.01 in order to identify additional genes that might also be considered bimodal with 
additional biological context, though only genes with p < 0.001 were included in our 
analysis to keep the false discovery rate low for the 9091 genes under consideration.  In 
order to investigate the effect of outliers on the prediction of bimodality from gene 
expression data, we ran the EM procedure again within the set of bimodal candidate 
genes leaving out the three highest expression values for each gene.  Five genes came out 
of the candidate list and are highlighted with an asterisk (*) in [83] Additional file 1 
though they were not excluded from our final list. 
 
 
Figure 12: Identification of switch-like genes with bimodal gene expression. A) The 
histogram and normal mixture probability density function (pdf) for a bimodal candidate 
gene. B) Bar graph representing gene set sizes during switch-like gene candidate 
selection process. 
 
This subset of genes was further reduced by the imposing the requirement that the 
standardized area of intersection A (indicating type I and type II error for the estimated 
bimodal distribution divided by the total area) was less than 0.10. This is clarified in 
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Figure 12A, where the dark grey region under the normal curves represents type I error 
and the solid black region under the normal curves represents type II error. The rationale 
for this step is that in order for switching to play a functional role within the cell, there 
must be minimal overlap between the two mixture components. This criterion reduced 
the number of candidate switch-like genes from 2166 to 1458.  In the resulting gene list, 
the standardized distance between components, D = (µ2 - µ1)/min(σ1, σ2), was at least 2.5 
for this remaining subset of switch-like gene candidates, confirming the statistical power 
of our analysis [115].  Figure 12B illustrates the reduction in switch-like gene candidates 
based on several cutoff values for the type I and II error rate.   
 
4.3.5 Assigning expression values to high/low modes for switch-like genes 
The switching threshold for each gene was defined at the intersection of the density 
curves for the two components of the mixture.  This switching threshold is mapped back 
onto the log RMA expression axis (labeled as XT in Figure 12A) with a reverse box-cox 
transformation.  A gene expression sample greater than XT for that gene was classified as 
having high expression, while a sample less than XT was classified has having low 
expression. Standardized area of intersection A was restricted to less than 0.1 in order to 
keep classification error to a minimum in the assignment of “high” and “low” states to 
switch-like genes.  
 
Developing a dendrogram for tissue similarity using the concept of tissue selectivity 
Nineteen tissue types for which we have extensive gene expression profiling have been 
clustered in dendrogram using a coexpression matrix.  Elements of the coexpression 
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matrix were selected from the larger gene set with the restriction that a gene in the subset 
must be expressed in the high mode for the majority of the samples in at least one tissue.  
For this purpose, the gene expression values for switch-like genes were converted to 
binary values corresponding to the high and low modes of two-component distribution.  
Gene expression within a single tissue type was modeled as a Bernoulli process (binomial 
distribution) with equal probabilities of high and low.  Based on this model, a gene that is 
not selectively expressed within a given tissue type should be evenly distributed between 
the high and low modes.  A gene that is selectively expressed within a given tissue type 
would show a significant bias for the high mode and low corresponding p-value.  We 
established p-values for a gene to be selectively expressed within each tissue type from 
the binomial distribution, where the number of trials equals the number of samples for 
that tissue type and the number of successes equals the number of samples with values in 
the high expression component.  Conversely, p-values for a gene to be selectively 
repressed within each tissue type were established based on the number of samples with 
values in the low expression component.  Tissue-selective genes were selected as those 
with p<0.01 for at least one of the nineteen general tissue types.   
 
4.3.6 Functional enrichment analysis 
KEGG pathway and GO annotations were used to compute functional enrichment scores 
for all switch-like genes.  Functional enrichment analysis was performed in Matlab by 
calculating the ratio of genes belonging to a functional category within a gene set of 
interest against the total number of genes belonging to that functional category within the 
set of genes on the MG-U74Av2 array.  Enrichment p-values were computed from a 
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hypergeometric distribution. The p-value cutoffs were selected at 0.01 for KEGG 
pathways and 0.001 for GO terms, to reduce the false discovery rate. The set of candidate 
bimodal genes contained 153 unique KEGG pathways and 321 unique GO cellular 
component terms, for which an expected 1.5 and 0.3 of the terms may appear significant 
by chance at these p-value cutoffs, respectively. 
 
4.3.7 Comparisons of health and disease states 
Additional MG-U74Av2 samples were used to identify alternate switching modes of 
switch-like genes in diabetes type I and II.  These samples are listed in Table 7 and 
represent adipose, heart, liver, skeletal muscle, pancreas, and peripheral blood.  Bimodal 
genes were identified as altered in disease for a single tissue by again modeling the 
samples as a binomial distribution.  Genes were identified as switching in the disease 
state when healthy samples have a significant p-value (less that 0.01) in one mode while 
disease samples have a significant p-value (less than 0.01) for the opposite mode. 
 
Table 7: Mouse gene expression datasets and tissue types composing our diabetes 
dataset. 
Diabetic Tissue Type Accession No. Source Samples 
Adipose (Type II) GSE2899 GEO 2 
Heart (Type I) GSE4616 GEO 6 
Liver (Type II) GSE2899 GEO 2 
Muscle (Type I) 
Muscle (Type II) 
GSE1659 GEO 6 
GSE2899 GEO 2 
Pancreas (Type I) 
Pancreas (Type II) 
GSE1623 
GSE2899 
GEO 
GEO 
6 
2 
Peripheral Blood (Type I) GSE1419 GEO 22 
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4.4 Results 
4.4.1 Identification of bimodal genes in the mouse genome 
Our method identified 1519 bimodal genes out of the 9091 unique genes (17%) on the 
MG-U74Av2 array.  The total number of bimodal genes was not sensitive to the p-value 
cutoff for bimodal versus skewed normal representations of the gene expression 
distribution within the ranges considered: the bimodal gene list increased by only three 
genes when the p-value was increased from 0.001 to 0.01.  Similarly, gene expression 
outliers were not important contributors to the bimodal gene list.  When we deleted the 
three largest gene expression values from the gene expression profile of each gene and 
ran our procedure for identification of bimodal genes, the resulting bimodal gene list 
turned out to be identical to our standard set of genes minus five genes.  Additional file 1 
in [83] contains a table providing a comprehensive list of bimodal genes for the mouse 
genome.  Columns of this table are composed of the following entities: Affymetrix probe 
ID, Entrez gene ID, gene symbol, human orthologs, log likelihood test statistic, estimated 
p-value, and maximum overlap A, representing the misclassification area between modes.  
Also listed for each gene in this table are parameters indicating the standardized distance 
between means D, the mixture parameter π, and the log RMA gene expression threshold 
value XT separating high and low expression modes.  The information on this table 
constitutes a priori data needed to identify the high expression or low expression modes 
of each gene in any given sample. The table can be used to identify altered modes of 
expression in disease states provided that these genes preserve their bimodal expression 
patterns.  The human orthologs of the bimodal mouse genes are listed in this table for 
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reference and their bimodal behavior in humans would have to be verified in future 
studies.   
 
4.4.2 Tissue similarity based on common modes of expression within bimodal genes 
Next we considered similarity of the nineteen tissues for which we had extensive 
microarray data.  As detailed in the methods section, we based our criteria of tissue 
similarity on the lists of tissue-selective bimodal genes in common within each unique 
pair of tissues.  Figure 13 indicates that commonality in the set of tissue-selective 
bimodal genes is indicative of tissue similarity.  The number of tissue-selective bimodal 
genes in the “high” mode for each tissue type is provided as the bottom number in the 
diagonal of Figure 13A, while the top number represents genes that may be considered 
tissue-specific; they are expressed in the “high” mode for that single tissue and the “low” 
mode for all others.  The remaining matrix elements of Figure 13A are the number of 
bimodal genes in the “high” mode for both of the two tissue types designated in the row 
and column headings.  We performed hierarchical clustering of the nineteen tissues based 
on sets of bimodal genes shared between them, to further demonstrate the role bimodal 
genes may play in tissue similarity.  The dendrogram in Figure 13B was computed using 
hierarchical clustering with average linkage, using one over the number of bimodal genes 
shared between two tissues (from Figure 13A) as the distance metric. In several 
examples, tissues with similar function cluster together, such as stomach and small 
intestine, heart and skeletal muscle, thymus and peripheral blood, and the reproductive 
tissues ovary and testis, while brain clusters distinctly apart from all other tissues.  Other 
groupings such as adipose, lung, adrenal, and epidermal tissue may occur because of 
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signaling motifs shared among these tissue types.  Our predications of tissue similarity 
are consistent with previous results that group human tissues by hierarchical clustering 
[23, 27]. 
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adipose 392 301 50 191 331 291 246 213 330 278 362 205 187 143 261 246 287 219 173
0
adrenal 301 412 99 201 316 301 283 236 311 264 308 247 185 146 274 241 288 260 171
160
brain 50 99 676 72 99 111 116 64 104 47 92 117 40 104 101 63 95 121 107
0
colon 191 201 72 310 234 188 210 176 256 194 211 164 137 143 275 192 250 170 184
1
epidermal 331 316 99 234 502 321 285 232 372 292 382 252 204 159 298 255 345 266 222
3
heart 291 301 111 188 321 515 277 212 315 245 403 217 186 130 258 217 285 226 160
0
kidney 246 283 116 210 285 277 409 229 302 238 272 230 200 138 286 222 285 228 184
0
liver 213 236 64 176 232 212 229 296 246 213 222 181 167 126 226 207 234 188 145
1
lung 330 311 104 256 372 315 302 246 548 282 387 241 196 196 332 304 344 260 262
0
mammary 278 264 47 194 292 245 238 213 282 338 285 193 196 131 259 230 271 201 167
8
muscle 362 308 92 211 382 403 272 222 387 285 582 223 201 169 297 289 321 236 203
0
ovary 205 247 117 164 252 217 230 181 241 193 223 426 159 172 235 261 232 353 173
0
pancreas 187 185 40 137 204 186 200 167 196 196 201 159 232 94 195 174 211 165 110
1
peripheral blood 143 146 104 143 159 130 138 126 196 131 169 172 94 337 177 207 150 174 200
0
small intestine 261 274 101 275 298 258 286 226 332 259 297 235 195 177 438 277 316 231 227
0
spleen 246 241 63 192 255 217 222 207 304 230 289 261 174 207 277 427 253 258 195
0
stomach 287 288 95 250 345 285 285 234 344 271 321 232 211 150 316 253 436 235 204
2
testis 219 260 121 170 266 226 228 188 260 201 236 353 165 174 231 258 235 446 181
0
thymus 173 171 107 184 222 160 184 145 262 167 203 173 110 200 227 195 204 181 369
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Figure 13: Tissue selective genes common among nineteen tissue types. A) The 
diagonal contains a top number corresponding to tissue-specific switch-like genes 
expressed in a given tissue and a bottom number identifying the total number of tissue-
selective switch-like genes expressed in that tissue. B)  A dendrogram representing tissue 
similarity based on tissue-selective expression of bimodal genes. 
 
 
4.4.3 Functional enrichment analysis indicates bimodal genes’ involvement with the 
extracellular environment 
Interaction with the extracellular environment appeared to be a common theme when we 
tested our bimodal gene subsets for enrichment among KEGG pathways and GO terms.  
Our findings for enriched KEGG pathways and GO categories are summarized in Table 8 
and Table 9, respectively.  The tables include enrichment scores, defined as the ratio of 
the observed number of genes over the expected number of genes from the subset of 
interest, and p-values for each entry calculated from a hypergeometric test [68] for the 
bimodal gene set against all unique genes on the MG-U74Av2 array.  KEGG pathways 
that were enriched for bimodal genes include cell communication, ECM-receptor 
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interaction, focal adhesion – all pathways that mediate cell communication with the 
extracellular environment (Table 8).  Figure 14 and Figure 15 identify the placement of 
bimodal genes (marked as orange) in ECM-receptor interaction and focal adhesion 
pathways, respectively.  Structural proteins that are bound by integrin receptors—collage, 
laminin and fibronectin subunits—are largely encoded by bimodal genes, confirming the 
fact that the multiple signaling roles of integrins are coupled with the extracellular 
environment [116].  The focal adhesion pathway shown in Figure 15 illustrates bimodal 
genes that mediate cell communication at the interior of the cell including genes that 
encode proteins involved in phosphorylation (ERK1/2, JNK, MEK1, MLCK, PAK, and 
PDK1).  Bimodal genes populate GO cellular component categories such as axons, basal 
lamina, basement membrane, cytoskeleton and extracellular matrix, and they are 
principally involved in the biological processes for ion transport, synaptic transmission, 
cytoskeletal organization and cell adhesion (Table 9).  The abundance of genes with 
bimodal expression within the cell communication, focal adhesion, and ECM pathways 
suggests aspects of these activities are enabled and disabled at the transcript level. 
Additionally, KEGG pathways for sugar metabolism are enriched with bimodal genes, 
reminiscent of the switch-like regulation of lactose metabolism in bacteria.  
 
Table 8: Enriched KEGG pathways for switch-like genes.  Enrichment scores are the 
number of observed genes over the number of expected genes.  P-values were computed 
using the hypergeometric distribution.  
KEGG pathway 
Genes
observed
Genes
expected
Ration of 
enrichment 
P-values
≤ 0.01
Cell Communication 35 14.37 2.44 1.01E-07 
ECM-receptor interaction 26 10.69 2.43 4.57E-06 
Focal adhesion 42 24.23 1.73 1.47E-04 
Fructose and mannose metabolism 13 5.68 2.29 2.18E-03 
Glycolysis / Gluconeogenesis 16 8.19 1.95 4.61E-03 
Long-term depression 17 9.36 1.82 8.07E-03 
Tight junction 24 12.87 1.87 1.23E-03 
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Table 9: Enriched GO terms for switch-like genes.  Terms are organized by cellular 
component (CC), biological process (BP), and molecular function (MF).  Enrichment 
scores are the number of observed genes over the number of expected genes.  P-values 
were computed using the hypergeometric distribution. 
 
GO term 
Genes 
observed
Genes 
expected
Ration of 
enrichment 
P-values 
≤ 0.001
CC 
axon 19 7.02 2.71 1.40E-05 
basal lamina 9 2.67 3.37 3.68E-04 
basement membrane 14 5.35 2.62 2.94E-04 
collagen 14 5.01 2.79 1.26E-04 
cytoskeleton 65 39.27 1.66 1.35E-05 
extracellular matrix 7 1.84 3.81 6.34E-04 
extracellular matrix (sensu Metazoa) 63 26.57 2.37 0.00E+00 
muscle myosin complex 6 1.17 5.13 1.30E-04 
postsynaptic membrane 18 7.85 2.29 3.20E-04 
sarcolemma 8 2.17 3.68 3.47E-04 
sarcoplasmic reticulum 6 1.34 4.49 4.44E-04 
synapse 24 9.52 2.52 5.03E-06 
synaptic vesicle 15 6.35 2.36 6.87E-04 
synaptosome 12 4.51 2.66 6.69E-04 
troponin complex 6 1.34 4.49 4.44E-04 
BP 
calcium ion transport 19 8.02 2.37 1.32E-04 
cell adhesion 88 50.79 1.73 4.41E-08 
cytoskeleton organization and 
biogenesis 
29 14.54 1.99 1.09E-04 
ion transport 62 42.11 1.47 7.54E-04 
muscle contraction 24 8.86 2.71 1.03E-06 
muscle development 21 9.19 2.29 1.10E-04 
regulation of long-term neuronal synaptic 
plasticity 
4 0.67 5.98 7.77E-04 
regulation of muscle contraction 14 3.01 4.65 1.97E-08 
striated muscle contraction 9 2.51 3.59 1.89E-04 
synaptic transmission 32 15.87 2.02 3.87E-05 
synaptogenesis 4 0.67 5.98 7.77E-04 
MF 
actin binding 41 24.39 1.68 3.61E-04 
calcium ion binding 113 78.70 1.44 2.03E-05 
creatine kinase activity 6 1.00 5.99 2.16E-05 
extracellular matrix structural 
constituent 
23 9.69 2.37 2.57E-05 
extracellular matrix structural 
constituent conferring tensile strength 
13 4.51 2.88 1.48E-04 
ion channel activity 44 25.40 1.73 1.05E-04 
kainate selective glutamate receptor 
activity 
4 0.67 5.98 7.77E-04 
motor activity 30 13.03 2.30 3.33E-06 
protein binding 502 443.45 1.13 1.87E-04 
structural constituent of cytoskeleton 29 13.70 2.12 3.17E-05 
structural constituent of muscle 15 4.01 3.74 5.99E-07 
structural molecule activity 64 37.76 1.69 6.88E-06 
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Figure 14: Bimodal genes highlighted in KEGG ECM-receptor interaction diagram. 
Nodes representing switch-like genes are colored orange; remaining genes on the MG-
U74Av2 array are shown in grey, and white blocks designate genes not on the array. 
Genes not in the organism-specific pathway for mouse are crossed out.  Genes identified 
as switching in skeletal muscle samples with diabetes type I and type II are labeled with 
“I” and “II”, respectively, with arrows indicating the direction of change in the disease 
state (▲is low-to-high; ▼ is high-to-low). 
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Figure 15: Bimodal genes highlighted in KEGG focal adhesion diagram. Nodes 
representing switch-like genes are colored orange; remaining genes on the MG-U74Av2 
array are shown in grey, and white blocks designate genes not on the array.  Genes 
identified as switching in skeletal muscle samples with diabetes type I and type II are 
labeled with “I” and “II”, respectively, with arrows indicating the direction of change in 
the disease state (▲is low-to-high; ▼ is high-to-low). 
 
 
4.4.4 Altered modes of bimodal genes in diabetes  
We identified bimodal genes that are expressed in an alternate mode within disease states 
for type I and type II diabetes. Comparisons of microarray samples for diabetes against 
samples for healthy tissue yielded nearly 200 genes with expression changes from “low” 
to “high” and “high” to “low” expression modes in skeletal muscle (Table 10).  Changes 
were dominated by switching from “high” to “low” in skeletal muscle in both type I and 
type II diabetes.  The bimodal genes with altered states in diabetes type I and II are 
enriched in pathways involved in communication and natural killer cell mediated 
cytotoxicity (Table 11).  The bimodal genes altered in diabetic skeletal muscle are 
66 
 
mapped onto the ECM-receptor interaction and focal adhesion pathways, shown in Figure 
14 and Figure 15, respectively.  As shown in these figures, collagen, fibronectin and 
tenascin are downregulated in diabetes type I and II transitioning from “high” to “low” 
expression whereas collagen receptor CD36 is switched from “low” to “high” expression 
in diabetes, perhaps as compensation for lower expression of extracellular matrix 
proteins.  The list of bimodal genes association with diabetes may provide clues as to the 
changes that occur in gene regulation pathways as a result of the disease.  Bimodal genes 
have also been implicated in congestive heart failure, Alzheimer's disease, 
arteriosclerosis, breast neoplasms, hypertension, myocardial infarction, obesity, and 
rheumatoid arthritis.  Future studies are needed for a comprehensive portrayal of their 
roles in these various diseases.  
 
 
Table 10: Switch-like genes identified in alternate modes of expression in diabetes.  
Quantities of bimodal genes that are in alternate modes between healthy tissue and 
disease tissue are shown for diabetes type I and II. 
 Tissue type: Adipose Heart Liver Muscle Pancreas 
Peripheral 
Blood 
Type I diabetes "low" to "high" --- 13 --- 37 16 9 
 "high" to "low" --- 9 --- 130 2 16 
Type II diabetes "low" to "high" 2 --- 11 25 16 --- 
 "high" to "low" 3 --- 14 142 3 --- 
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Table 11: Enriched KEGG pathways for switch-like genes identified in alternate 
modes of expression in diabetes.  Enriched KEGG pathways are shown for bimodal 
genes that switch states between healthy tissue and type I and II diabetes (T1 and T2, 
respectively).  Enrichment scores are the number of observed genes over the number of 
expected genes.  P-values were computed using the hypergeometric distribution. 
 
Tissue  KEGG pathway 
Genes 
observed
Genes 
expected
Ration of 
enrichment P ≤ 0.01
T1 
Heart --- --- --- --- --- 
Muscle 
Antigen processing and 
presentation 
9 1.05 8.60 8.11E-07 
Cell communication 7 1.58 4.43 9.89E-04 
Cell adhesion molecules (CAMs) 8 1.73 4.63 3.19E-04 
ECM-receptor interaction 7 1.18 5.95 1.60E-04 
Focal adhesion 9 2.66 3.38 1.38E-03 
Leukocyte transendothelial 
migration 
8 1.58 5.06 1.72E-04 
Natural killer cell mediated 
cytotoxicity 
6 1.67 3.59 6.47E-03 
Type I diabetes mellitus 5 0.77 6.48 9.67E-04 
Pancreas 
Benzoate degradation via 
hydroxylation 
1 0.01 101.01 9.86E-03 
Leukocyte transendothelial 
migration 
3 0.17 17.62 6.02E-04 
Tight junction 2 0.15 13.12 9.92E-03 
Peripheral 
blood 
--- --- --- --- --- 
T2 
Adipose --- --- --- --- --- 
Liver PPAR signaling pathway 2 0.15 13.47 9.52E-03 
Muscle 
Antigen processing and 
presentation 
8 1.05 7.64 8.42E-06 
Cell communication 6 1.58 3.80 4.92E-03 
Cell adhesion molecules (CAMs) 8 1.73 4.63 3.19E-04 
ECM-receptor interaction 6 1.18 5.10 1.09E-03 
Leukocyte transendothelial 
migration 
8 1.58 5.06 1.72E-04 
Natural killer cell mediated 
cytotoxicity 
6 1.67 3.59 6.47E-03 
Type I diabetes mellitus 5 0.77 6.48 9.67E-04 
Pancreas --- --- --- --- --- 
 
 
4.4.5 Transcription factors and bimodal gene expression  
Approximately 15% of transcription factors are bimodal. Comparison of our bimodal 
gene list with the transcription factor list obtained from the Transfac Professional 
Database [108, 109] revealed 76 out of a total 525 transcription factors on the MG-
U74Av2 array as bimodal (Additional File 3 in [83]).  In turn, binding sites for these 
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transcription factors have been identified for 91 genes with Entrez gene IDs, 79 of which 
were on the MG-U74Av2 array.  Only 25 out of these 79 genes were bimodal, indicating 
that the set of bimodal transcription factors may not be solely responsible for their 
regulation. Nevertheless, genes that are regulated or co-regulated by bimodal 
transcription factors are enriched in some of the same KEGG pathways as bimodal genes 
(Table 12), including cell communication and ECM-receptor interaction.  The GO 
categories for the genes co-regulated by switch-like transcription factors also intersect 
with GO categories of switch-like genes that are not transcription factors (Table 13).  As 
the list of known transcription factors and their binding sites grow in the near future, 
more definitive relationships between bimodal genes and transcription factors are likely 
to emerge.  
 
Table 12: Enriched KEGG pathways for genes regulated by switch-like 
transcription factors.  Enrichment scores are the number of observed genes over the 
number of expected genes.  P-values were computed using the hypergeometric 
distribution.   
KEGG pathway 
Genes
observed
Genes
expected
Ration of 
enrichment 
P-values
≤ 0.01
Antigen processing and presentation 6 0.64 9.40 3.07E-05 
Cell adhesion molecules (CAMs) 5 0.97 5.17 2.54E-03 
Cell Communication 5 1.01 4.96 3.05E-03 
Circadian rhythm 3 0.19 16.19 6.45E-04 
ECM-receptor interaction 4 0.74 5.40 5.94E-03 
Maturity onset diabetes of the young 3 0.43 6.94 8.55E-03 
PPAR signaling pathway 5 0.82 6.07 1.22E-03 
Type I diabetes mellitus 7 0.56 12.60 7.63E-07 
Type II diabetes mellitus 4 0.66 6.07 3.86E-03 
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Table 13: Enriched GO terms for genes regulated by switch-like transcription 
factors. Terms are organized by cellular component (CC), biological process (BP), 
and molecular function (MF).  Enrichment scores are the number of observed genes 
over the number of expected genes.  P-values were computed using the hypergeometric 
distribution. 
GO term 
Genes 
observed
Genes 
expected
Ration of 
enrichment 
P-values 
≤ 0.001
CC 
collagen type I 2 0.04 48.58 4.18E-04 
external side of plasma membrane 6 0.93 6.48 2.70E-04 
extracellular matrix (sensu Metazoa) 8 1.63 4.92 1.80E-04 
extracellular region 14 4.43 3.16 9.44E-05 
extracellular space 30 13.44 2.23 5.68E-06 
MHC class I protein complex 3 0.14 20.82 2.77E-04 
BP 
antigen processing and presentation of 
endogenous peptide antigen via MHC 
class I 
2 0.04 48.58 4.18E-04 
antigen processing and presentation of 
peptide antigen via MHC class I 
3 0.14 20.82 2.77E-04 
defense response 6 1.01 5.95 4.34E-04 
glucose transport 4 0.23 17.67 4.92E-05 
immune response 11 3.23 3.40 3.07E-04 
rhythmic process 3 0.19 16.19 6.45E-04 
MF 
extracellular matrix structural constituent 5 0.56 9.00 1.84E-04 
structural constituent of bone 2 0.04 48.58 4.18E-04 
 
 
4.5 Discussion 
This article presents a comprehensive list of bimodal genes in the mouse genome.  We 
used an automated statistical algorithm that is similar to the approach used in the 
detection of bimodality in blood glucose distribution [110, 111] in order to identify 
bimodal, switch-like genes in a large-scale microarray database for murine tissue.  
Bimodal gene expression is either in a “high” or “low” expression mode, indicating 
switch-like regulation at the transcript level.  Our automated analysis revealed over 15% 
of the genes in the mouse genome as bimodal (switch-like).  These bimodal genes are 
enriched in cell communication pathways and are also enriched in such biological 
processes as cell adhesion, synaptic transmission, and ion transport.  Moreover, bimodal 
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genes associate with a large number of disease types including diabetes type I and II, 
hypertension, and cancer. Because a large portion of bimodal gene products are 
positioned in the extracellular region, the list we present in this study provides potential 
biomarker targets for early detection and accurate classification of complex diseases.  
 
Although we have paid considerable attention to the statistics of identifying bimodal 
genes from the large-scale microarray data, our list of bimodal genes may change with 
time as microarray data obtained with the same Affymetrix system expands to include 
tissue types not considered in this study.  Nevertheless, the list that we present in this 
article is stable under deletion of gene expression outliers from the data. Although, as 
discussed in the Background section, a number of genes from various species have been 
identified in the literature as bimodal or switch-like previously, to our knowledge, the list 
that we present (1519 genes) is yet the most comprehensive and contains important 
information on gene regulation in health and disease at the transcript level.  Although the 
list annotates bimodal genes for the murine genome, their orthologs presented for the 
human genome provide a core candidate list for the bimodal genes in the human genome. 
Our automated method for annotating bimodal genes will yield a comprehensive list for 
the human genome with the availability of a comprehensive set of standardized 
microarray data for large numbers of well controlled tissue samples.  
 
Recent literature points to examples of bimodal genes involved in feedback and 
feedforward motifs in gene regulation networks [117-119].  Bimodal gene expression 
associated with switch-like regulation was shown to be a direct consequence of DNA 
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methylation at cis-regulatory sequences at least in the case of E-coli metabolic gene 
circuitry [120].  This observation is consistent with our finding that only a small number 
of transcription factors are bimodal and those transcription factors in turn only regulate a 
small portion of the remaining bimodal genes. 
 
Our study indicates that in a number of complex diseases such as diabetes type I and II, 
the stable inheritance of the normal mode of expression in bimodal genes is 
compromised.  For example, bimodal genes coding for collagen subunits are “low” rather 
than “high” in skeletal muscle for diabetes type I and II relative to healthy samples.  In 
addition, type II diabetes has the fibronectin subunit gene “low” rather than “high” in the 
same tissue. Perhaps, in compensation, collagen receptor CD36 becomes highly 
expressed in both diabetes types.  Our comprehensive list of bimodal genes in the mouse 
will be useful in identifying disease-phenotypic alterations in gene regulation in diseases 
such as cancer, hypertension and diabetes.  
 
For the interest of assessing the diagnostic potential of switch-like genes as biomarkers, 
we compared our switch-like gene list with previously published lists of serum proteins 
and disease genes. Mouse orthologs were obtained for serum proteins identified in the 
HuPO PPP, including the 3020 two-plus peptide list and 889 high-confidence lists [104, 
105]. We found that nearly a quarter of the high-confidence plasma proteins were 
bimodal. Although these results may change as more accurate proteomic measurements 
are available, it indicates the potential of switch-like genes as biomarkers for the 
classification of disease subtypes.  
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We compared our list of bimodal genes with disease gene sets for mouse obtained from 
the RGD Disease Portal [103].  On the average, we identified that bimodal genes account 
for 15% of the genes within disease gene lists for congestive heart failure, Alzheimer's 
disease, arteriosclerosis, breast neoplasms, cerebrovascular accident, hypertension, 
myocardial infarction, obesity, rheumatoid arthritis, and diabetes mellitus types I and II.  
Among these bimodal genes, 30% were serum protein encoding genes, suggesting their 
potential to serve as biomarkers.   
 
4.6 Conclusions 
This research identified a large set of mouse genes as switch-like by assembling and 
analyzing a large collection of microarray data encompassing diverse tissue types. Genes 
with bimodal, switch-like control were shown to be enriched within the cell 
communication pathways and the extracellular environment. The modes of expression for 
a large majority of such genes were tissue-selective.  Moreover, a significant number of 
these switch-like genes switched between modes of expression in diabetic compared to 
healthy samples in a number of tissue types. These findings comprise an important first 
step in identifying altered states of gene switches in complex diseases such as 
hypertension, obesity and cancer. 
 
Bimodal expression implicates strong regulation at the transcript level.  Switch-like 
regulation can influence protein activity in cases where protein abundance parallels 
transcript level, as is observed with proteins such as cytokines [121, 122]. Bimodal gene 
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expression provides a means for the cell to enable and disable pathway functions at the 
transcript level. Genes with bimodal, switch-like control are involved in communication 
pathways that play crucial roles in determining cell phenotype through interaction with 
the extracellular environment in health and disease. Because their expression is tightly 
regulated at the transcription level, they comprise a candidate set of biomarkers for a 
large number of disease states. 
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Chapter 5: Human Switch-Like Genes and Their Regulation via Transcription 
Initiation and Histone Methylation 
 
5.1 Summary 
This chapter expands on the identification of bimodal genes presented in Chapter 4 by 
identifying and annotating bimodal genes in the human genome and presenting an 
analysis of regulatory mechanisms contributing to bimodality in gene expression.  This 
work is adapted from a manuscript recently submitted to BMC Genomics (Ertel and 
Tozeren, 2008 II).  Gene expression is controlled over a wide range at the transcript level 
through complex interplay between DNA and regulatory proteins, resulting in profiles of 
gene expression that can be represented as normal, graded, and bimodal (switch-like) 
distributions.  We have previously performed genome-scale identification and annotation 
of genes with bimodal, switch-like expression at the transcript level in the mouse, using 
large microarray datasets for healthy tissue, in order to study the cellular pathways and 
regulatory mechanisms involving this class of genes.  We showed that a large population 
of bimodal mouse genes encoding for cell membrane and extracellular matrix proteins 
involved in communication pathways.  This study expands on previous results by 
annotating human bimodal genes, investigating their correspondence to human orthologs 
of mouse bimodal genes and exploring possible regulatory mechanisms that contribute to 
bimodality in gene expression in human and mouse.   Fourteen percent of the human 
genes on the HGU133A array (1847 out of 13076) were identified as bimodal or switch-
like.  More than 40% were found to have bimodal mouse orthologs. KEGG pathways 
significantly enriched for bimodal genes included ECM-receptor interaction, focal 
adhesion, and tight junction, showing strong similarity to the results obtained in mouse.  
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Similarly, the GO biological process “cell adhesion” and cellular component 
“extracellular matrix” were significantly enriched.  Promoter analysis using the 
mammalian promoter database revealed a slight bias for TATA boxes within the set of 
bimodal genes.  An analysis of alternative transcription start sites curated in the database 
of transcription start sites revealed a higher than average number of transcription start 
sites associated with bimodal genes.  Histone methylation data available for a small 
number of tissues provided the strongest association to bimodal genes, with differentially 
methylated histones appearing 50% more frequently in the promoters of bimodal genes at 
high state of activation.  Human genes with bimodal expression were enriched within the 
cell membrane and extracellular environment.  The set of bimodal genes is also enriched 
for TATA boxes - a regulatory feature previously associated with precise control of gene 
expression.  Moreover, transcription of bimodal genes is associated with histone 
methylation.  The list of human bimodal genes can be used in identifying biomarkers for 
tissue specificity and our method of identifying bimodality can be expanded to disease 
states for accurate disease subtyping and biomarker development. Aberrant patterns of 
histone methylation have known associations with complex diseases, such as cancer, 
providing further potential for the use of bimodal genes as biomarkers, as the mode of 
expression can provide insight to the histone methylation status. The method presented 
allows for an alternate approach to differential gene expression analysis between tissues 
and disease subtypes.   
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5.2 Background  
Our recent work applied an automated high-throughput method to classify genes with 
bimodal expression profiles within the mouse genome based on microarray experiments 
performed on healthy tissues using the Affymetrix MGU74Av2 microarray platform [83].  
The identification of genes with bimodal expression is useful to identify the biological 
variation of genes that are tightly regulated around two discrete levels at the transcript 
level [119].  Many of the bimodal genes were expressed in “high” or “low” modes on a 
tissue-dependent basis.  Enrichment analysis using Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathways [35] and Gene Ontology (GO) annotation [34] within this 
set of bimodal genes revealed that they are utilized in cell-cell communication and 
communication with the extracellular environment.  We had also evaluated the 
expression of the bimodal genes in disease states for diabetes types I and II to reveal 
some of these genes altered modes of expression in the disease state, revealing the roles 
of these genes in cell communication and immune response.  As a natural extension of 
this work, we have applied the same automated high-throughput method to classify genes 
with bimodal expression in the human genome and compared the list with human 
orthologs of mouse bimodal genes.  Moreover, we looked into the transcript-level 
regulation of bimodal genes using a variety of bioinformatics databases. 
The detection of bimodal genes in human is useful for determining a set of genes tightly 
controlled around two states at the transcript level.  Additionally, the identification of 
these bimodal genes provides an indication of how well the previous methods extend 
across species and different microarray platforms.  While it is expected that many 
orthologs between human and mouse would share patterns of regulation such as 
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bimodality, the literature has also documented that many gene regulation promoters have 
changed over the course of evolution between human and mouse [123]. Genes with 
bimodal expression profiles in both organisms may indicate conservation of alternate 
promoters, which have been implicated in tissue-specific expression common among the 
bimodal genes.  Alternately, genes with known orthologs that have been identified as 
bimodal in only one of these species, may illustrate the instability in mammalian 
promoters [123, 124].  Investigation of the regulatory mechanisms at play in the 
expression of bimodal genes should provide insight into the stability of their expression 
as well as how these genes may lose regulation in the process of disease [125].  
There are many factors contributing to the regulation of transcription, having varying 
impact in the difference in expression level and the time scale over which the expression 
level may change, either within a cell or over a course of cell divisions.  Transcription 
factors may enhance or inhibit expression as they bind to regulatory gene promoters 
effecting transcription initiation [126].  Changes in transcription factor activity may 
account for bimodality in genes within a single tissue over time, such as in circadian 
rhythm pathways [127].  Transcript-level regulation may also be achieved through 
epigenetic modification, such as CpG island methylation, which inhibits transcription 
either at the promoter region or downstream [128, 129].  Additional epigenetic 
mechanisms, including histone modifications such as methylation and acetylation were 
shown to be associated with transcription initiation and elongation [130].  These 
epigenetic regulatory mechanisms may be linked with bimodality resulting from 
differentiated tissues, where stable modifications maintain a high mode of expression in a 
select number of tissues, and a low mode of expression in others.  Regulatory 
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mechanisms mentioned above may work in combination to produce a variety of 
expression profiles, where even in bimodal genes one mechanism may account for 
expression level changes within a single mode of expression and an alternate regulatory 
mechanism may account for expression level changes between modes of expression. 
In this study, we extend our classification of bimodal genes to the human genome.  Our 
results indicate that a sizable number of genes with bimodal expression in mouse are also 
bimodal in human, with recurring roles of cell-cell communication and communication 
with the extracellular environment.  Furthermore, the set of bimodal genes identified by 
our method shows a strong connection to epigenetic regulation, namely methylation of 
histone tails in gene promoter regions. 
 
5.3 Methods  
5.3.1 Data Selection  
Human gene expression microarray datasets were obtained from both the Gene 
Expression Omnibus (GEO) [98, 99] and ArrayExpress [100, 101] online repositories.  
For the purpose of comparing a subset of human bimodal genes with those identified in 
mouse, we created a microarray dataset with comparable tissue samples to those used in 
the mouse study (Table 14) [83].  In order to adequately represent some tissue types, it 
was necessary to combine datasets from Affymetrix HGU133A and HGU133plus2 
arrays, which have 22,277 probesets in common.  
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Table 14: Microarray datasets used in this study representing normal human tissue.  
The number of tissue samples used in the previous work that identified bimodal genes in 
mouse are included in parentheses 
Tissue Samples (Used in mouse study) 
adipose 10 (6) 
adrenal 10 (6) 
brain 89 (89) 
colon 10 (5) 
epidermal 25 (25) 
heart 38 (38) 
kidney 10 (3) 
liver 10 (8) 
lung 26 (26) 
mammary 15 (15) 
muscle 64 (64) 
ovary 10 (10) 
pancreas 6 (5) 
peripheral_blood 12 (12) 
small_intestine 7 (3) 
spleen 12 (12) 
stomach 10 (1) 
testis 38 (49) 
thymus 5 (11) 
Total 407 (388) 
 
5.3.2 Microarray normalization  
Affymetrix probe intensities were filtered to exclude probesets that are not shared 
between the HGU133A and HG133plus2 microarrays.  The remaining probesets 
normalized using the RMA background correction, quantile normalization, and 
summarization approach for large datasets described as the refRMA algorithm [55].  
RMA background adjustment was performed on each chip.  Quantile normalization was 
performed by computing probe-level quantiles from an 800-array (HGU133plus2) 
training set and applying these quantiles to additional HGU133A arrays as they were 
added to the dataset.  RMA summarization was performed by median polishing on the 
800-array training set and storing the row effects to be applied to additional arrays as they 
were added to the dataset. 
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5.3.3 Gene annotation  
Annotation for Entrez Gene ID, EMBL accession, gene symbol, and gene ontology 
biological process, cellular component, and molecular function were retrieved from the 
HGU133plus2 annotation file updated March 2008 on the Affymetrix website [10].  
KEGG pathway descriptions were retrieved April 29th, 2008 from the KEGG ftp site [35, 
131].  Orthologous gene pairs between mouse and human were identified using the 
EMBL accession number database from OMA browser [132, 133], dated November 
2007, in addition to matching official gene symbols.  The data was then imported to 
Matlab R2007b (The Mathworks Inc., Natick, MA, USA), where all subsequent 
procedures were implemented.  
 
5.3.4 Identification of bimodal genes in the human genome  
Bimodal genes were identified in the human genome by fitting a two-component mixture 
model, as detailed in the methods of our previous work [83].  Briefly, we tested the 
hypothesis H1 that gene expression distribution follows a two-component (bimodal) 
mixture against the hypothesis H0 of a single normal distribution, adjusted for skewness 
using a box-cox transformation.  The log likelihood ratio test statistic -2logλ was 
computed for the two-component mixture hypothesis H1 versus the null hypothesis H0 of 
a single component.  Candidates for bimodal “switch-like” genes were selected as those 
with p-values no more than 0.001 based on a chi-square distribution with six degrees of 
freedom at the values of -2logλ.  This subset of genes was further reduced by the 
imposing the requirement that the standardized area of intersection A (indicating type I 
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and type II error for the estimated bimodal distribution divided by the total area) was less 
than 0.10.  
 
5.3.5 Functional enrichment analysis  
KEGG pathway and GO annotations described above were used to compute functional 
enrichment scores for all switch-like genes. Functional enrichment analysis was 
performed in Matlab by calculating the ratio of genes belonging to a functional category 
within a gene set of interest against the total number of genes belonging to that functional 
category within the 22277 common probesets between the HGU133A and HGU133plus2 
arrays.  Enrichment p-values were computed from a hypergeometric distribution [68].  
The p-value cutoffs were selected at 0.01 for KEGG pathways and 0.001 for GO terms, to 
reduce the false discovery rate. The set of candidate bimodal genes was distributed 
among 186 unique KEGG pathways and 618 unique GO cellular component terms, for 
which an expected 1.9 and 0.6 of the terms may appear significant by chance at these p-
value cutoffs, respectively.  
 
5.3.6 Promoter analysis 
The set of bimodal genes was evaluated for regulatory mechanisms including the core 
promoter type and the number of alternate promoters.  Genes were separated into subsets 
of bimodal and non-bimodal for promoter analysis to evaluate differences within each of 
human and mouse.  Promoter sites and sequence motifs were obtained from MPromDB 
[134].  Promoters corresponding to the targets of transcription factors were mapped to the 
sets of bimodal and non-bimodal genes using Entrez gene ID.  The remaining promoter 
82 
 
types seldom appeared and were bundled together into an "other" category.  The 
frequency that each of these regulatory sites, including AP-1, AP-2, SP1, TATA and 
CAAT-signal, appear within bimodal genes and non-bimodal genes was assessed for the 
bimodal and non-bimodal subsets in human and mouse.  Additional annotation for human 
and murine genes describing the number of alternative promoter sites (hspromoter.tab for 
human and mmpromoter.tab for mouse, both dated June 12th, 2007) were downloaded 
from the database of transcriptional start sites (DBTSS) [135].  The distribution of 
alternative promoters was computed as a histogram within the sets of bimodal genes and 
non-bimodal genes within human and mouse.  The statistical significance for two, three, 
four, and two or more promoters was estimated using the hypergeometric distribution. 
 
5.3.7 Analysis of DNA methylation effect on mode of expression 
DNA methyaltion was explored as a regulatory mechanism for bimodal genes due to its 
known association with gene silencing.  CpG methylation data was obtained from 
Illingworth at al. supplementary information Dataset S1 [136].  This dataset documents 
methylation sites for roughly 8% of the human genome across four tissues - blood, brain, 
muscle, and spleen.  The frequency of methylation sites that were mapped to 5', 3', and 
intragenic regions of known genes was computed and significance of enrichment within 
bimodal genes was estimated from the hypergeometric distribution.  This methylation 
data was also used to evaluate correspondence between methylation status within either 
the 5' or intragenic regions and the mode of expression in bimodal genes.  Genes were 
assigned to a mode of expression within each of the four tissues by treating expression 
measurements within each tissue as Bernoulli trials against the binomial distribution, as 
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described in [83].  The frequency of DNA methylation was then calculated in the subsets 
of "high" and "low" genes for each of the four tissues. 
 
5.3.8 Comparison of histone methylation enrichment versus mode of expression 
The final regulatory mechanism that was assessed for a contribution to bimodal gene 
expression was histone methylation.  Methylation data was obtained from Guenther et al. 
Table S3 and Table S4, which describes H3K4me3 enrichement scores and locations 
across the human genome for three cell types: human embryonic stem cells (hES), liver 
cells (hepatocytes), and B-cell lymphocytes [130].  Enrichment scores for H3K4me3 
designated as high-confidence in Guenther et al. were used to create a gene set for each 
of these three tissue types [130].  Two addition gene sets were created based on 
differential H3K4me3 enrichment for liver versus H9 hES cells and for B-cells versus H9 
hES cells.  For example, the liver versus H9 hES gene set includes those enriched with 
high confidence in liver but not H9 hES cells in addition to those with high confidence in 
H9 hES cells but not liver.  The frequency of histone methylation sites based on these 
three tissues as well as the differentially enriched sites was evaluated for the sets of 
bimodal genes and non-bimodal genes within human.  Additionally, the significance of 
each list of sites was evaluated using the hypergeometric distribution. 
To further investigate the interplay between histone methylation and bimodal gene 
expression, we gathered additional microarray samples corresponding to H9 stem cells 
(samples GSM249282, GSM225045, and GSM38629, from datasets GSE9865, 
GSE8884, and GSE2248, respectively) and evaluated the mode of expression for bimodal 
genes within that those H9 stem cells as well as liver samples within our dataset.  Using 
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the binomial distribution approach detailed in [83], we identified a group of bimodal 
genes as I) "high" in liver but "low" in stem cells, II) "low" in liver but "high" in stem 
cells, and III) expressed in common modes between these two tissues ("high" in both or 
"low" in both).  These three subsets were then used to create a scatter plot of H3K4me3 
enrichment, excluding genes with enrichment scores below a 2-fold enrichment in both 
hES and hepatocytes. 
 
5.4 Results  
5.4.1 Identification of bimodal genes in the human genome  
Microarray data for tissue types listed in Table 14 were used to identify bimodal genes in 
the human genome.  Two-component mixture analysis of the 13076 unique genes 
represented in both Affymetrix HGU133A and HGU133plus2 microarrays identified 
1847 genes, or 14%, as bimodal, with p<0.001.  Among these genes with orthologs in 
mouse, 42% were identified in our previous study on MGU74Av2 microarrays.  The 
probability of obtaining this overlap from a random selection of genes, estimated from 
the hypergeometric distribution, is indistinguishable from zero.  Additional file 2 in [137] 
provides the list of bimodal genes accompanied by the mouse ortholog, as well as the p-
value and threshold between high and low modes of expression, XT.  
 
5.4.2 Functional enrichment analysis highlights themes of cell communication 
Enrichment of KEGG pathways and GO terms extended the theme of communication 
with neighboring cells and the extracellular environment that was also evident from 
bimodal genes in mouse.  Enriched KEGG pathways are presented in Table 15, while 
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enriched GO terms are detailed in Table 16, including listings for cellular component, 
biological process, and molecular function terms.  A majority of the KEGG pathways 
identified as enriched for bimodal genes in mouse were also significantly enriched in 
humans (Table 15).  The most highly populated pathways common to bimodal human 
genes and human orthologs for bimodal mouse genes are the calcium signaling, focal 
adhesion and tight junction pathways.  The cell communication pathways ECM-receptor 
interaction and focal adhesion, which were identified as significant within the last study, 
again appeared as highly populated with bimodal genes.  The KEGG ECM-receptor 
interaction pathway is shown in Figure 16, with enriched nodes highlighted in orange, 
and nodes replicated in the mouse study highlighted in yellow.  The figure shows integrin 
subunits a7, B1, and B6 and a subset of their receptors including multiple collagen types 
I, II, and IV, fibronectin and laminin as bimodal, as would be expected since these 
proteins contribute to tissue specificity. Also identified bimodal are the cell membrane 
receptors CD44, SV2, CD36, and Syndecan. The KEGG focal adhesion pathway, which 
also interacts with the ECM, is depicted in Figure 17.  The figure shows the bimodal 
genes are not only positioned at ECM and cell membrane but also at different stages of 
cell signaling, indicating the dominant role bimodal genes play in the processing of 
crosstalk between cells and the ECM. Proteins that are deemed as bimodal in this 
pathway include EGF, ELK1, FYN, HGF, vinculin, actinin and cyclins D1 and D2. 
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Table 15: KEGG pathway enrichment for human switch-like genes.  KEGG pathways enrichment was computed using the set of 
human bimodal genes as well as human orthologs for the previously identified bimodal genes in mouse.  Italicized values do not meet 
p-value threshold for significance.  Pathways enriched in both bimodal human genes and the set of human orthologs derrived from 
bimodal mouse genes are shown in bold. 
 Human bimodal genes Human orthologs from bimodal mouse genes 
KEGG Pathway 
Genes
Observed 
Genes
Expected 
Ration of
Enrichment 
P-values <= 
0.01 
Genes
Observed 
Genes
Expected 
Ration of
Enrichment 
P-values <= 
0.01 
Adherens junction 20 10.17 1.97 1.81E-03 4 2.38 1.68 2.14E-01 
Alanine and aspartate metabolism 10 3.96 2.53 3.57E-03 4 0.93 4.32 1.28E-02 
Calcium signaling pathway 44 23.31 1.89 1.54E-05 13 5.45 2.38 3.28E-03 
Carbon fixation 9 2.97 3.03 1.29E-03 4 0.69 5.77 4.50E-03 
Cell Communication 25 16.10 1.55 1.53E-02 19 3.77 5.04 5.49E-09 
Cell adhesion molecules (CAMs) 36 16.81 2.14 4.31E-06 6 3.93 1.53 2.01E-01 
Citrate cycle (TCA cycle) 11 3.53 3.12 2.85E-04 4 0.83 4.84 8.57E-03 
ECM-receptor interaction 20 11.58 1.73 8.98E-03 13 2.71 4.80 2.61E-06 
Endometrial cancer 14 7.06 1.98 7.76E-03 2 1.65 1.21 4.96E-01 
Focal adhesion 50 26.84 1.86 6.22E-06 22 6.28 3.50 3.13E-07 
Fructose and mannose metabolism 7 4.94 1.42 2.17E-01 5 1.16 4.32 5.51E-03 
Gap junction 24 13.14 1.83 2.03E-03 10 3.07 3.25 9.75E-04 
Glycolysis / Gluconeogenesis 18 7.91 2.28 4.64E-04 8 1.85 4.32 4.70E-04 
Glyoxylate and dicarboxylate metabolism 4 1.55 2.57 5.75E-02 3 0.36 8.26 4.85E-03 
Leukocyte transendothelial migration 28 15.11 1.85 7.12E-04 11 3.54 3.11 8.07E-04 
Long-term depression 18 10.45 1.72 1.31E-02 9 2.44 3.68 7.11E-04 
Long-term potentiation 20 9.32 2.15 5.47E-04 7 2.18 3.21 5.94E-03 
MAPK signaling pathway 50 34.61 1.44 4.14E-03 13 8.09 1.61 6.33E-02 
Melanogenesis 23 12.57 1.83 2.44E-03 5 2.94 1.70 1.71E-01 
Neurodegenerative Diseases 12 5.23 2.30 3.67E-03 4 1.22 3.27 3.29E-02 
PPAR signaling pathway 19 8.62 2.21 5.10E-04 8 2.02 3.97 8.44E-04 
Pathogenic Escherichia coli infection - EHEC 18 6.92 2.60 6.73E-05 5 1.62 3.09 2.23E-02 
Pathogenic Escherichia coli infection - EPEC 18 6.92 2.60 6.73E-05 5 1.62 3.09 2.23E-02 
Pentose phosphate pathway 8 3.53 2.27 1.81E-02 4 0.83 4.84 8.57E-03 
Pyruvate metabolism 11 5.09 2.16 8.75E-03 2 1.19 1.68 3.35E-01 
Reductive carboxylate cycle (CO2 fixation) 5 1.27 3.93 4.29E-03 2 0.30 6.73 3.36E-02 
Regulation of actin cytoskeleton 51 27.54 1.85 6.10E-06 13 6.44 2.02 1.28E-02 
Tight junction 39 17.09 2.28 2.87E-07 14 4.00 3.50 4.50E-05 
Type I diabetes mellitus 13 5.65 2.30 2.49E-03 3 1.32 2.27 1.45E-01 
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Table 16: Gene Ontology enrichment for human switch-like genes.  GO category enrichment was computed using the set of human 
bimodal genes as well as human orthologs for the previously identified bimodal genes in mouse.  Italicized values do not meet p-value 
threshold for significance.  GO terms enriched in both bimodal human genes and the set of human orthologs derived from bimodal 
mouse genes are shown in bold. 
  Human bimodal genes Human orthologs from bimodal mouse genes 
Gene Ontology 
Genes
Observed 
Genes
Expected 
Ration of
Enrichment 
P-values <= 
0.01 
Genes
Observed 
Genes
Expected 
Ration of
Enrichment 
P-values <= 
0.01 
CC actin cytoskeleton 36 15.68 2.30 6.87E-07 9 3.67 2.45 1.12E-02 
 cell junction 62 37.01 1.68 2.09E-05 27 8.66 3.12 1.62E-07 
 cell projection 23 11.02 2.09 3.38E-04 7 2.58 2.72 1.44E-02 
 clathrin coat of trans-Golgi network vesicle 6 1.27 4.72 4.51E-04 N/A N/A N/A N/A 
 collagen 7 2.83 2.48 1.60E-02 5 0.66 7.57 3.95E-04 
 costamere 4 0.57 7.08 3.97E-04 1 0.13 7.57 1.26E-01 
 cytoplasm 527 408.92 1.29 0.00E+00 153 95.64 1.60 7.08E-11 
 cytoskeleton 110 57.49 1.91 0.00E+00 33 13.45 2.45 1.85E-06 
 extracellular region 175 172.89 1.01 4.42E-01 67 40.44 1.66 2.31E-05 
 growth cone 10 2.68 3.73 8.41E-05 6 0.63 9.56 2.36E-05 
 integral to plasma membrane 184 148.88 1.24 9.15E-04 46 34.82 1.32 3.11E-02 
 membrane 680 577.01 1.18 2.03E-08 169 134.96 1.25 2.51E-04 
 membrane fraction 97 66.25 1.46 5.02E-05 31 15.49 2.00 1.93E-04 
 muscle myosin complex 12 2.54 4.72 4.94E-07 8 0.59 13.45 4.35E-08 
 myosin complex 21 6.92 3.03 9.19E-07 11 1.62 6.79 4.23E-07 
 neuromuscular junction 6 0.85 7.08 7.89E-06 2 0.20 10.09 1.50E-02 
 phosphopyruvate hydratase complex 3 0.42 7.08 2.81E-03 3 0.10 30.27 3.58E-05 
 plasma membrane 239 192.10 1.24 9.90E-05 71 44.93 1.58 5.97E-05 
 postsynaptic membrane 19 12.71 1.49 4.48E-02 10 2.97 3.36 7.53E-04 
 proteinaceous extracellular matrix 52 33.62 1.55 7.38E-04 25 7.86 3.18 3.25E-07 
 sarcoplasmic reticulum 14 2.40 5.83 5.39E-10 7 0.56 12.46 5.97E-07 
 sarcoplasmic reticulum lumen 3 0.42 7.08 2.81E-03 3 0.10 30.27 3.58E-05 
 sarcoplasmic reticulum membrane 6 1.27 4.72 4.51E-04 2 0.30 6.73 3.36E-02 
 smooth endoplasmic reticulum 4 0.85 4.72 4.69E-03 3 0.20 15.13 6.65E-04 
 striated muscle thick filament 12 2.26 5.31 6.39E-08 6 0.53 11.35 7.59E-06 
 synapse 41 22.04 1.86 4.26E-05 21 5.15 4.07 4.34E-08 
 troponin complex 5 0.99 5.06 9.16E-04 4 0.23 17.30 3.80E-05 
  Z disc 9 1.98 4.55 2.24E-05 3 0.46 6.49 9.93E-03 
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Table 16 (Continued) 
 
  Human bimodal genes Human orthologs from bimodal mouse genes 
Gene Ontology 
Genes
Observed 
Genes
Expected 
Ration of
Enrichment 
P-values <= 
0.01 
Genes
Observed 
Genes
Expected 
Ration of
Enrichment 
P-values <= 
0.01 
BP antigen processing and presentation of 
peptide antigen via MHC class I 
7 1.41 4.96 8.99E-05 1 0.33 3.03 2.85E-01 
 cell adhesion 112 65.68 1.71 3.76E-09 36 15.36 2.34 1.84E-06 
 cell differentiation 72 47.88 1.50 1.99E-04 24 11.20 2.14 3.80E-04 
 central nervous system development 25 12.01 2.08 1.99E-04 9 2.81 3.20 1.93E-03 
 cytoskeleton organization and biogenesis 24 10.74 2.24 7.75E-05 9 2.51 3.58 8.65E-04 
 dephosphorylation 24 10.88 2.21 9.77E-05 5 2.54 1.97 1.11E-01 
 glycogen metabolic process 12 4.24 2.83 4.44E-04 4 0.99 4.04 1.63E-02 
 glycolysis 19 7.06 2.69 2.44E-05 9 1.65 5.45 3.24E-05 
 ion transport 83 62.01 1.34 2.89E-03 38 14.50 2.62 5.48E-08 
 multicellular organismal development 136 102.41 1.33 2.26E-04 35 23.95 1.46 1.56E-02 
 muscle contraction 39 12.43 3.14 0.00E+00 24 2.91 8.26 0.00E+00 
 muscle development 29 10.03 2.89 2.95E-08 13 2.35 5.54 4.73E-07 
 negative regulation of protein kinase activity 7 2.26 3.10 3.94E-03 6 0.53 11.35 7.59E-06 
 nervous system development 79 42.38 1.86 1.36E-08 36 9.91 3.63 0.00E+00 
 neuromuscular synaptic transmission 5 0.85 5.90 2.96E-04 3 0.20 15.13 6.65E-04 
 neuron differentiation 13 4.66 2.79 3.08E-04 5 1.09 4.59 4.25E-03 
 neuron migration 12 4.10 2.93 3.05E-04 3 0.96 3.13 6.94E-02 
 protein amino acid dephosphorylation 29 15.54 1.87 5.06E-04 5 3.63 1.38 2.99E-01 
 regulation of heart contraction 13 3.96 3.29 4.01E-05 6 0.93 6.49 2.55E-04 
 regulation of muscle contraction 8 1.84 4.36 1.03E-04 4 0.43 9.31 6.63E-04 
 regulation of striated muscle contraction 6 1.13 5.31 1.71E-04 5 0.26 18.92 1.98E-06 
 regulation of the force of heart contraction 5 0.85 5.90 2.96E-04 2 0.20 10.09 1.50E-02 
 sensory perception of sound 33 15.26 2.16 8.44E-06 10 3.57 2.80 3.02E-03 
 striated muscle contraction 21 4.10 5.13 0.00E+00 10 0.96 10.44 1.59E-08 
 synaptic transmission 35 24.01 1.46 1.28E-02 23 5.62 4.10 8.88E-09 
 transport 218 188.15 1.16 8.19E-03 77 44.01 1.75 6.23E-07 
 tricarboxylic acid cycle 10 3.39 2.95 9.10E-04 3 0.79 3.78 4.33E-02 
  very-long-chain fatty acid metabolic process 5 0.99 5.06 9.16E-04 2 0.23 8.65 2.05E-02 
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Table 16 (Continued) 
  Human bimodal genes Human orthologs from bimodal mouse genes 
Gene Ontology 
Genes
Observed 
Genes
Expected 
Ration of
Enrichment 
P-values <= 
0.01 
Genes
Observed 
Genes
Expected 
Ration of
Enrichment 
P-values <= 
0.01 
MF actin binding 78 34.32 2.27 0.00E+00 16 8.03 1.99 6.91E-03 
 
alpha-amino-3-hydroxy-5-methyl-4-
isoxazole propionate selective glutamate 
receptor activity 3 0.42 7.08 2.81E-03 3 0.10 30.27 3.58E-05 
 calcium ion binding 145 103.40 1.40 8.50E-06 51 24.18 2.11 3.24E-07 
 calmodulin binding 37 16.95 2.18 1.93E-06 14 3.96 3.53 4.10E-05 
 extracellular matrix structural constituent 18 10.88 1.65 1.96E-02 11 2.54 4.32 4.22E-05 
 GTPase activity 43 24.15 1.78 8.61E-05 14 5.65 2.48 1.62E-03 
 heparin binding 18 10.17 1.77 9.85E-03 9 2.38 3.78 5.80E-04 
 ion channel activity 48 36.02 1.33 2.15E-02 26 8.42 3.09 3.39E-07 
 long-chain-fatty-acid-CoA ligase activity 6 1.41 4.25 9.92E-04 2 0.33 6.05 4.11E-02 
 microfilament motor activity 9 2.40 3.75 1.82E-04 4 0.56 7.12 1.99E-03 
 motor activity 33 14.69 2.25 3.40E-06 17 3.44 4.95 4.75E-08 
 NAD binding 13 4.52 2.88 2.14E-04 2 1.06 1.89 2.86E-01 
 nucleotide binding 235 206.37 1.14 1.34E-02 75 48.27 1.55 6.23E-05 
 phosphoprotein phosphatase activity 31 15.96 1.94 1.52E-04 5 3.73 1.34 3.18E-01 
 phosphopyruvate hydratase activity 3 0.42 7.08 2.81E-03 3 0.10 30.27 3.58E-05 
 phosphoric monoester hydrolase activity 25 11.87 2.11 1.61E-04 5 2.78 1.80 1.45E-01 
 protein binding 777 677.86 1.15 1.68E-07 201 158.55 1.27 1.32E-05 
 protein tyrosine phosphatase activity 25 12.43 2.01 3.59E-04 5 2.91 1.72 1.66E-01 
 structural constituent of bone 3 0.71 4.25 2.25E-02 3 0.17 18.16 3.41E-04 
 structural constituent of cytoskeleton 32 12.15 2.63 8.12E-08 16 2.84 5.63 1.76E-08 
 structural constituent of muscle 28 5.65 4.96 0.00E+00 14 1.32 10.59 0.00E+00 
 structural molecule activity 81 42.52 1.91 3.01E-09 34 9.94 3.42 3.06E-10 
 
transferase activity, transferring phosphorus-
containing groups 7 1.55 4.51 2.17E-04 3 0.36 8.26 4.85E-03 
 transporter activity 61 40.68 1.50 6.35E-04 16 9.51 1.68 2.99E-02 
  voltage-gated ion channel activity 25 16.81 1.49 2.53E-02 12 3.93 3.05 5.64E-04 
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Figure 16: KEGG ECM-receptor interaction pathway enriched by human switch-
like genes.  Nodes enriched for human bimodal genes are colored orange, while nodes 
also identified as bimodal in mouse orthologs are emphasized in bold.  In all, the overlap 
between bimodal human and bimodal mouse orthologs contains thirteen unique genes 
represented in seven unique nodes in the ECM-receptor pathway.  Nodes colored in gray 
were not identified as bimodal, while white nodes are used for genes that are not 
represented on the HGU133A array. 
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Figure 17: KEGG Focal adhesion pathway enriched by human switch-like genes 
shown in yellow and orange.  Nodes enriched for human bimodal genes are colored 
orange, while nodes also identified as bimodal in mouse orthologs are emphasized in 
bold.  In all, the overlap between human and mouse orthologs contains twenty-two 
unique genes represented in nine unique nodes in the focal adhesion pathway.  Nodes 
colored in gray were not identified as bimodal, while white nodes are used for genes that 
are not represented on the HGU133A array.  
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5.4.3 Promoter analysis reveals bias for TATA boxes in bimodal genes 
The mammalian promoter database (MPromDB) [134] was used to assess the distribution 
of common promoter types within the set of bimodal genes.  MPromDB contained 
promoters for 840 genes represented on the HGU133 arrays and promoters for 536 genes 
represented on the MGU74Av2 array.  The frequencies of the common promoter types 
AP-1, AP-2, SP1, TATA and CAAT are illustrated in Figure 18 A and B for the sets of 
bimodal and non-bimodal genes in human and mouse, respectively.  The remaining 
promoter types seldom appeared and were bundled together into an "other" category.  
The set of bimodal genes within human and mouse shows a statistically significant bias 
for TATA promoters, with significance of p = 9.5e-5 for human and p = 4.9e-7 for 
mouse, estimated from a hypergeometric distribution.  The remaining promoter types 
present between bimodal and non-bimodal genes revealed no significant differences that 
were consistent between human and mouse, suggesting that bimodality in gene 
expression is largely independent of the regulatory promoter type.  The SP1 and AP1 
promoters appeared underrepresented in mouse bimodal genes, but this result is based on 
only a small subset of genes and was not consistent with the results in human.  
 
5.4.4 Alternative promoter sites more common in bimodal genes 
The database of transcription start sites (DBTSS) [135] was used to evaluate the number 
of alternative promoters associated with genes in the bimodal and non-bimodal subsets 
for human and mouse.  The distribution of alternate promoters was shifted towards a 
higher number of promoters per gene for those with bimodal distributions, as shown in 
Figure 18 C and D, providing evidence for some contribution towards the dynamic range  
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Figure 18: Summary of promoter usage between bimodal and non-bimodal subsets.  
The relative frequency of core promoter types cataloged in MPromDB [134] is shown for 
bimodal and non-bimodal gene subsets in A) human and B) mouse.  The number of 
alternative promoters per gene is shown for bimodal genes and non-bimodal genes for C) 
human and D) mouse.  For a subset of bimodal genes with multiple alternative promoters, 
tissue-dependent alternative promoters from DBTSS [135] corresponded to the mode of 
expression, as shown for glutamate receptors E) GRIA2 in human and F) Gria1 in mouse.
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of gene expression required for bimodality.  When compared against non-bimodal genes, 
two or more promoters are more common in bimodal genes for both human and mouse, 
with a respective significance level of p ≈ 0 and p = 1.9e-8, estimated from a 
hypergeometric distribution.  Multiple promoters per gene may be prevalent but not 
required for bimodal expression.  Alternative promoter sites in human and mouse were 
tested for tissue-selective usage corresponding to the mode of expression for bimodal 
genes.  Alternative promoters for 168 bimodal genes in human were identified as 
corresponding with the mode of expression across within the nineteen tissues.  
Alternative promoter data wasn't available for skeletal muscle tissue in mouse, but data 
for the remaining 18 tissues identified 131 genes with at least one alternative promoter 
corresponding to the mode of expression.  Random permutation of the tissue labels was 
used to estimate a median false discovery rate of 4%.  Though there was no overlap 
between these tissue-selective promoter gene sets in human and mouse, there were 
several pathways in common for this comparison, including the neuroactive ligand-
receptor interaction, gap junction, and calcium signaling pathway.  The alternative 
promoters identified as corresponding to the mode of expression in both human and 
mouse were largely brain-specific.  For example, the genes GRIA2 in human and Gria1 
in mouse encoding for glutamate receptor proteins in the neuroactive ligand-receptor 
interaction pathway were associated with multiple alternative promoters specific to 
brain.  Expression box plots across the nineteen tissues having at least one promoter 
specific to brain, is shown in Figure 18 E and F for human GRIA2 and mouse Gria1 
genes, respectively.  These results indicate that multiple alternative promoters may 
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provide redundancy and that a single mode of expression does not necessarily correspond 
with a unique alternative promoter. 
 
5.4.5 DNA methylation shows a negligible contribution to bimodal gene expression  
Cytosine methylation has been shown to provide a heritable mechanism in mammals for 
altering DNA-protein interactions [128].  Genes can be transcribed from methylation-free 
promoters even though adjacent transcribed and nontranscribed regions are extensively 
methylated. Methylation of CpG-rich promoters prevents transcriptional initiation 
ensures the silencing of genes in the X Chromosome [128].  Recent data by Illingworth et 
al. [136] allowed us to investigate aspects of epigenetic regulation for their contribution 
to bimodal gene regulation.  These authors surveyed methylation within blood, brain, 
muscle, and spleen and obtained lists of genes with methylated CpG islands in 5', 
intragenic, and 3' regions, which mapped to roughly 6-8% of human genes.  The genes 
identified with intragenic DNA methylation were more common among the set bimodal 
genes, suggesting that the inhibitory effect of DNA methylation on transcription 
elongation [129] may be a regulatory mechanism for bimodal genes.  We also used the 
methylation data from Illingworth et al. [136] to test the relationship between DNA 
methylation status and the mode of expression within bimodal genes.  The results varied 
for each tissue type, with the largest differences being decreased DNA methylation in 
bimodal genes with a "high" mode of expression in brain and increased DNA methylation 
in bimodal genes with a "high" mode of expression in muscle.  DNA methylation is 
typically considered a gene silencing mechanism, which would correspond to low 
expression.  However, the very small portion of genes represented in the CpG island 
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methylation data for these four tissues may not be an adequate set to observe a consistent 
trend. 
 
5.4.6 Histone methylation provides a switching mechanism for bimodal genes 
Next, we considered the possible role of epigenetic regulation as a switching mechanism 
for bimodal genes.  A recent dataset that mapped histone modifications across the human 
genome for three cell types, including human embryonic H9 stem cells (hES), liver cells 
(hepatocytes), and B-cell lymphocytes [130] was used to evaluate the enrichment of 
histone 3 lysine 4 trimethylation (H3K4me3) at the promoters of bimodal genes.  The 
H3K4me3 enrichment based on each of these three tissue types did not suggest a role in 
the regulation of bimodal genes (Figure 19A).  However, if histone methylation provided 
a switching mechanism for bimodal gene expression, this would be evident in the 
differential methylation between tissue types, and not methylation status pertaining to a 
single tissue type.  We used the data from these three tissues to create lists of genes with 
differentially enriched H3K4me3 regions for liver versus H9 hES cells and for B-cells 
versus H9 hES cells.  These set of differentially enriched H3K4me3 regions appeared 
with 50 to 100% higher frequency in bimodal genes compared to non-bimodal genes, as 
seen in Figure 19A.  To further investigate the correlation between histone methylation 
and bimodal gene expression, we gathered additional microarray samples corresponding 
to H9 stem cells (GEO dataset accession numbers GSE9865, GSE8884, and GSE2248) 
and evaluated the mode of expression for bimodal genes within those H9 stem cell 
samples as well as liver samples within our dataset.  We identified a group of bimodal 
genes as I) "high" in liver but "low" in stem cells, II) "low" in liver but "high" in stem 
97 
 
cells, and III) expressed in common modes between these two tissues ("high" in both or 
"low" in both).  These results are plotted in Figure 19B.  Group I (green "+" symbols in 
Figure 19B) had a corresponding increase in methylation enrichment for liver vs. stem 
cells for nearly 85% of the genes, while group I (blue "x" symbols in Figure 19B) had a 
corresponding decrease in liver vs. stem cells for 77% of the genes.  Approximately, 65% 
of the remaining bimodal genes expressed in common modes between these two tissue 
types (black points in Figure 19B) were within the standard deviation around the line 
y=x.  These results demonstrate a strong association between histone methylation status 
and the mode of expression for bimodal genes. 
 
 
Figure 19: Bimodal gene enrichment for promoter region methylation of lysine 4 of 
histone H3 (H3K4me3).  A)  Fraction of bimodal vs. non-bimodal genes enriched for 
histone methylation within their promoters as reported by Guenther et al. [130] for H9 
hES cells, liver (hepatocytes), and B-cells.  The fourth and fifth sets of bars represent the 
set of genes enriched at high confidence within one tissue but not the other liver versus 
hES cells and B-cell versus hES cells.  B)  H3K4me3 enrichment ratio from Guenther et 
al. [130] for liver vs. stem cells is shown for bimodal genes.  Genes expressed with 
"high" mode in liver and "low" mode in H9 stem cells are shown with green "+" symbols, 
while bimodal genes expressed with "low" mode in liver and "high" mode in stem cells 
are shown with blue "x" symbols.  Black points are used for the remaining bimodal genes 
expressed in common modes between these two tissue types.  The standard deviation 
around the line y=x (solid red line) is shown as dashed red lines.   
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5.5 Discussion  
In this study, using a large-scale microarray database, we have annotated 1847 human 
genes as having bimodal gene expression profiles.  A recent study used again a large 
human microarray dataset for cancer samples to identify nearly 800 bimodal genes with 
the employment of a model-based clustering algorithm [125].  A comparison of their list 
against our list of bimodal genes resulted in 285 common elements, suggesting that 
bimodal genes in our list may not perform as bimodal in disease states in addition to 
possible switching of expression state in a disease state from one mode to another. Even 
in healthy tissue comparison, orthology argument did not entirely preserve bimodality in 
mouse and human data.  Nearly 40% of the genes in this list corresponded to human 
orthologs of mouse bimodal genes that were annotated in our previous study [83].  
Bimodality within 40% of human-mouse orthologs can be viewed as substantial overlap 
when considering that besides measurement noise and slightly different tissue types 
represented by datasets for each organism, there exist differences in transcript sequences 
and transcript regions targeted by the microarray probes for orthologous genes among the 
two species.   Further differences in gene expression between the two species arise from 
changes in regulatory sequences resulting from evolution [123, 124].  This overlap 
demonstrates some degree of stability of bimodality in these datasets, even though we did 
not force identical tissue type quantities between the two organisms. 
 
Our study shows that bimodal genes make a large contribution to the proteins composing 
the extracellular matrix as well as external membrane proteins.  Within the cell 
membrane side of the ECM-receptor interaction pathway, integrin subunits α7, β1, and 
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β6 were identified as bimodal, while several others, including α2-α6 and β3-β5 a were 
not.  This finding suggests integrin complex are regulated by an interplay of transcript-
level regulation as well as previously shown post-translational modifications [138, 139].  
In addition, several bimodal genes in the focal adhesion pathway are linked to 
phosporylation of Beta-catenin, a key element in the Wnt - signaling pathway, which 
plays a functional role in cell fate , proliferation, and apoptosis [140].  The Wnt-signaling 
pathway is active in development and is also a culprit in disease such as colorectal cancer 
and melanomas [140, 141].  As such, bimodal genes upstream from these interactions 
provide potential markers for tissue-specific signaling as well as metabolic and chronic 
diseases. 
 
Bimodality implies high level transcription level regulation, and bimodal genes may act 
as switches in the direction of signals and/or metabolic flow. Our study shows that 
bimodality appears to arise independently from the type of promoter present, even though 
we estimate the number of TATA boxes in bimodal genes is enriched, appearing in over 
80% of bimodal genes with documented promoter sites.  This may merely reflect a bias in 
gene annotation, as the involvement of these genes among pathways of interest, such as 
MAPK signaling and ECM-receptor interaction, may draw more focus for 
experimentation.  The number of alternative (promoter) transcription start sites appears to 
have an influence on the bimodality of gene expression.  Unlike the limited number of 
experimentally produced promoter binding sites, alternative promoter sites have been 
assessed by genome-wide mapping of transcript 5' ends [135].  While the number of 
known alternate promoter start sites for bimodal genes is shifted to a higher number than 
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for non-bimodal genes, it is not sufficient to explain the phenomenon of bimodality.  
Additionally, previous studies investigating the usage of alternate promoters by gene 
ontology cellular component reveal that genes with several alternate promoters play a 
role in signaling, but do not contribute to the extracellular region, suggesting a difference 
from the set of bimodal genes [142].  This still allows for bimodal genes to include a 
subset of genes with a higher than average number of alternate promoters that work in 
concert with other regulatory mechanisms such as DNA methylation and histone 
modification. 
 
We have shown that bimodal gene expression has a bias for multiple alternative 
promoters, as well as an association with histone methylation (H3K4me3), though a 
complete description of the links between all possible regulatory mechanisms cannot be 
made with currently available data.  A recent study has shown that CpG-specific RNA 
polymerase II binding, associated with transcription initiation, is conserved among 
different tissue types [143]. A large portion of these may constitute the set of 
housekeeping genes, while others may appear at high modes of expression in some 
tissues, while silenced in other tissues via CpG methylation.  A link has also been 
demonstrated between DNA methylation and histone methylation, where genes that 
undergo transcription initiation require H3K4 methylation as well as unmethylated DNA 
[144, 145].  Consistent with our findings in this study, H3K4 trimethylation was 
previously associated with transcriptionally active genes [146]. The presence or absence 
of this modification can achieve switch-like regulation [147, 148].  Histone methylation, 
alongside DNA methylation, is a key player in cell differentiation during development 
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and maintain cell lineage [136, 149].  This stable regulation also maintains the balance 
between cell communication molecules and the extracellular environment [150].  
Aberrant histone methylation patterns are among the epigenetic modifications that give 
rise to cancer [151].  As the mode of expression for bimodal genes is closely related to 
H3K4me3 status, gene expression levels may be used as a surrogate for detecting 
aberrant patterns of methylation associated with disease. While our knowledge of 
methylation associated with gene regulation may be incomplete, genes regulated through 
alternative promoters have an additional layer of complexity, as they can have largely 
different methylation status at individual promoters from tissue to tissue [152].  The 
regulatory mechanism for bimodal genes may therefore include a complex logic of DNA 
and histone methylation among alternative promoters, in addition to positive and negative 
regulation through transcription factor binding.  
 
Alternate splicing events may present another explanation for bimodality in the 
expression of genes.  Alternative-splicing isoforms have been identified as tissue-specific 
[153].  A substantial portion of alternative splicing isoforms are also associated with 
nonsense-mediated mRNA decay [154].  Three out of five genes identified with muscle-
specific alternative splicing in Xu et al. [153] (PDLIM7, TPM2, and FHL1) were 
identified as bimodal and expressed in "high" mode in our microarray data for muscle but 
not other tissues.  Five out of the twenty-two genes identified as having brain-specific 
alternative splicing in Xu et al. [153], were identified as having bimodal expression, but 
only one of these (CDC42) was expressed in a brain-specific manner.  This indicates the 
possibility that stable transcript splice isoforms account for the high mode of expression 
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in specific tissues, while alternative splice isoforms undergo nonsense-mediated decay. 
The methylation/promoter analysis presented here is a first step towards understanding 
the complex interplay of various molecular mechanisms affecting transcription in human 
and mouse genomes. 
 
5.6 Conclusions 
This research expanded our representation of "switch-like" gene expression by cataloging 
the bimodal genes evident in human microarray data for diverse tissue types.  Results 
obtained from human data affirm that genes with bimodal, switch-like expression play a 
large role in cells communication with the extracellular environment.  Equally as 
important, our results indicate bimodal genes capture epigenetic aspects of gene 
regulation, indicative of stable, inheritable levels of expression.  These findings verify 
that biologically relevant information can be inferred from bimodal distributions, much in 
the way that housekeeping genes have been used. Because the threshold between "high" 
and "low" expression modes corresponds well expression with histone methylation 
enrichment in promoter regions, bimodal genes may serve as biomarkers for complex 
diseases such as cancer, where aberrant histone methylation is a known factor in disease 
progression.  Through the identification of condition-specific modes of expression within 
healthy tissue and disease subtypes, the method presented allows for an alternate 
approach to differential gene expression analysis. 
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Chapter 6: Conclusions and Remarks 
 
This work extended the application of pathway analysis used for identifying trends in 
gene regulation towards the analysis of bimodal, “switch-like” genes that have distinct 
“on” and “off” modes of expression.  Our findings demonstrate that by applying changes 
in gene expression to the context of pathways, more consistent trends are apparent than 
when viewing expression on a gene-by-gene basis.  This was first demonstrated for our 
comparisons of normal, tumor, and cell line samples, where although changes in gene 
expression ranged from subtle to extreme, we identified consistent trends in the use of 
metabolic and signaling pathways.  Pathway analysis was also useful in viewing common 
trends among different organisms.  While the analysis of normal, tumor, and cell line 
samples allowed for subtle changes in gene expression, our identification of bimodal 
genes in human and mouse focuses on genes with distinctly separate modes of 
expression.  Overlap between human bimodal genes and the set of human orthologs 
mapped from mouse bimodal genes was less than 50%, though many cell communication 
pathways, such as ECM-receptor interaction and tight junction were enriched for bimodal 
genes within both organisms.   
 
The genome-scale identification and annotation of genes with bimodal, switch-like 
expression at the transcript level in human and mouse provide a basis for studying 
regulatory mechanisms including as well as the cellular pathways involving this class of 
genes.  This work has served to link the class of genes with bimodal expression in human 
and mouse to biologically relevant regulation events at both the genetic and epigenetic 
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level.  At the nucleotide sequence level of regulation, TATA box promoters and genes 
with multiple alternative promoters make a contribution to bimodal gene expression.  At 
the epigenetic level, histone methylation plays a role in the expression of bimodal genes, 
as the mode of expression corresponds well with histone methylation status.  CpG 
dinucleotide methylation may also tie in to this form of regulation.  While genome-wide 
data for CpG methylation is lacking, studies have shown that CpG methylation and 
histone modifications are closely related [129, 144, 145].  A combination of regulatory 
mechanisms utilizing alternative promoters and mechanisms inducing epigenetic 
modifications may very well work synergistically for the expression of some genes, as 
methylation status can change dynamically over alternative promoters for a single gene 
[152].  In the future, datasets revealing histone methylation status in a wider range of 
tissue types will be useful in further understanding this mechanism and refining the list of 
genes whose bimodality results purely from this mode of regulation. 
 
Bimodal genes also have applications in the study of diseases.  Several bimodal genes 
were shown to have altered modes of expression in diabetic mouse models.  This may 
help researchers to focus on the subset of genes with altered modes of regulation versus 
those with moderate changes that are a consequence or compensation related to the 
disease state.  Additionally, the association with histone methylation status observe in 
human has implications for the study of complex diseases.  Recent work has shown that 
diabetes causes variations in histone methylation within peripheral blood monocytes 
[155].  Aberrant histone methylation has also been implicated in some forms of cancer 
[151].  
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The results presented herein include a novel annotation representing bimodal genes 
within the human and mouse genomes.  Canonical biological pathways present a global 
view of biological molecules and their relationships to one another.  Pathway analysis 
assists in the interpretation of molecular profile data by providing biological context.  In a 
similar manner, bimodal gene expression distributions provide biological context that can 
be used to view genes as active or inactive.  Previous approaches to determine the 
presence or absence of transcript-level expression, such as the MAS5 algorithm, are 
based on statistical but not biological context and have been the subject of some criticism 
[47-49].  The mode of expression in human bimodal genes was demonstrated to have a 
biological context, as it is associated with histone methylation status [137].  The lists of 
bimodal genes we have identified in the human and mouse genomes provide a new set of 
a priori knowledge than can be applied to future biological studies.  Additionally, our 
implementation of the refRMA workflow was trained on over 800 human microarray 
samples and can now be used to bring additional human microarray samples to the same 
level of normalization scale for robust analysis.  The set of samples used to identify 
bimodal genes in human and mouse is most likely far from saturated, and it is expected 
that the annotation of bimodal genes will change over time as more data is available.  The 
refRMA workflow provides an ideal framework for expanding on the existing dataset as 
more microarray samples become available. 
 
One aspect of gene expression regulation that has recently come to light, but was not 
addressed in this study is the suppression of gene transcripts by micro RNAs (miRNAs).  
MicroRNAs play a regulatory function by sequence-specific pairing with mRNA 
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transcripts in order to inhibit translation into proteins or mediate mRNA degradation 
[156-158].  The regulatory influence enacted by miRNAs can affect a large number of 
genes on a tissue-specific manner [159, 160].  There are currently a few hundred known 
miRNAs, but knowledge of their targets is incomplete [161].  As there are a limited 
number of validated miRNA targets, computational prediction of miRNA targets is an 
attractive approach for genome-wide identification of transcripts that undergo post-
transcriptional regulation [162, 163].  The tissue-specific modes of expression identified 
in bimodal genes provide new knowledge that may be used for predicting miRNA targets 
in a tissue-specific manner.  The regulatory roles of microRNA appear to be an important 
mechanism for development in addition to tissue-specific gene expression [156, 158, 
164].  Additionally, the function of miRNA has been associated with both histone and 
DNA methylation, both of which have been shown to play a key role in development 
[165-168].  The association of differential methylation with altered modes of bimodal 
gene expression between embryonic stem cells and adult liver indicates the involvement 
of regulatory mechanisms over the course of development.  The large sets of microarray 
data used for the identification of bimodal, switch-like genes in human and mouse 
provides a reference for analyzing additional samples in the context of development.  
Microarray datasets representing stem cells and developmental time course may be easily 
added to the existing data for diverse tissue types in human and mouse.  Future studies 
may take advantage of the groundwork presented here for identifying modes of 
expression and regulatory events over the time course of development, as bimodal genes 
may switch between modes to achieve terminally differentiated tissue types. 
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